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CHAPTER I 
 
 INTRODUCTION 
 
I.A.  Embryo Implantation 
Implantation is the process by which an embryo comes into physical and 
physiological contact with uterine endometrium.  Early pregnancy failure often 
arises due to defects that occur before, during or immediately after implantation.  
Even with in vitro fertilization and embryo-transfer techniques, implantation rates 
remain low in humans, most often as a result of embryos being transferred into 
nonreceptive uteri 1.  Studying the molecular interactions that regulate 
implantation will provide a better understanding of these signaling pathways, 
eventually leading to new approaches to prevent implantation failure. 
Mouse models have provided insight into the molecular basis of human 
implantation, since there are certain similarities between mouse (Figure 1) and 
human implantation.  For example, in both mice and humans decidualization and a 
hemochorial type of placentation take place.  Also, embryos from both species 
embed in the antimesometrial stroma 2.  With the initiation of implantation, uterine 
stromal cells undergo proliferation and differentiate to decidual cells, creating an 
intrauterine environment conducive to embryonic development and growth.  
Reported functions of decidual cells include providing nutritional support to the 
embryo prior to establishment of a functional placenta 3, controlling embryonic 
trophoblast cell invasion 4, and attenuating maternal immune responses against 
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the embryo carrying paternal genes 5.  A detailed account of cellular events 
crucial to successful implantation can be found in Chapter II.   
Implantation involves the interplay of numerous signalling molecules, yet 
the hierarchical instructions that coordinate the embryo–uterine dialogue are not 
well understood.  One major difficulty in clearly defining this discourse is the 
complexity of the implantation process involving heterogeneous cell types of both 
the uterus and blastocyst, each containing unique molecular signatures which 
show dynamic changes during the course of pregnancy.   
While gene expression studies by in situ hybridization or 
immunohistochemistry have shown differential expression patterns of specific 
genes during implantation, there is no report how numerous proteins and other 
signaling molecules are spatially displayed at specific times and stages of 
implantation in the context of blastocyst-uterine juxtaposition.  The goal of this 
study was to use Imaging Mass Spectrometry (IMS) to analyze molecular 
changes in the embryo and uterus during the periimplantation period, day 4 to 
day 8, of mouse pregnancy. 
 
I.B.  Imaging Mass Spectrometry 
Matrix-Assisted Laser Desorption/Ionization (MALDI) IMS can be used to 
localize specific molecules such as drugs, lipids, peptides and proteins directly 
from fresh frozen tissue sections with a lateral image resolution up to 50 µm 6.  
The size of the substructures or features of interest, for each tissue type, 
determines the lateral image resolution.  Thin frozen sections (10-15 µm thick) 
3 
 
are cut and thaw-mounted on target plates; subsequently, an energy absorbing 
matrix is applied.  Laser ablation give rise to ionic molecular species that are 
recorded according to their mass-to-charge (m/z) values.  Thus, a single mass 
spectrum is acquired from each ablated spot in the array.  Signal intensities at 
specific m/z values can be exported from this array to give a two-dimensional ion 
density map, or image, constructed from the specific coordinate location of that 
signal, and its corresponding relative abundance.  For images, matrix is 
deposited in a homogeneous manner to the surface of the tissue in such a way 
as to minimize the lateral dispersion of molecules of interest.  Selected matrix 
deposition techniques are illustrated in Figure 2, left.  For example, to analyze 
proteins, peptides, drugs or phospholipids matrix can be deposited on the tissue 
by robotically spraying a continuous coating or by automatically printing arrays of 
small droplets.  Recently, it has been found that ‘dry coating’ the tissue with a 
uniform layer of small matrix crystals (< 20 µm) can be used to obtain high lateral 
resolution phospholipids images 7.  As displayed in this figure, each micro spot or 
pixel coordinate is then automatically analyzed by MALDI Mass Spectrometry 
(MS).  From the analysis of a single section, images at virtually any molecular 
weight may be obtained provided there is sufficient signal intensity to record.  
Examples of molecular images acquired from a day 6 implantation site tissue 
section are located in Figure 2, right. 
One of the most compelling aspects of IMS is that it provides the ability to 
simultaneously visualize the spatial arrangement of hundreds of analytes directly 
from tissue without any prior knowledge or need for target specific reagents such 
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as antibodies.  IMS also enables the visualization of post translational 
modifications and proteolytic processing while retaining spatial localization.  
Other MS techniques, such as secondary ionization mass spectrometry (SIMS), 
have also seen use for a variety of imaging applications.  One of the major 
advantages of SIMS is that it is capable of high resolution imaging,  around or 
better than 1 μm for small molecules (m/z <1000 Da) and elements, respectively 
8.  However, thus far, it has not been shown to be effective for the analysis of 
proteins and large peptides.   
The following sections will focus on MALDI IMS analysis of proteins and 
phospholipids in terms of basic instrumentation, sample preparation and recent 
applications.  IMS has been shown to be an effective technology for discovery for 
both qualitative and relative quantitative analysis of normal and disease tissue 
and for assessing temporal changes in biological systems 6.  In addition, this 
technology has been applied for the generation of three-dimensional protein 
images of brain, whole body reconstructions and the measurement of protein 
changes in specific tissues after systemic drug administration 9-11.   
 
I.B.i.  The Technology 
The MS instrumentation best suited for in-situ analysis of proteins and 
phospholipids directly from tissue sections is MALDI time-of-flight (TOF) 
technology.  The ablation process directed by the focused laser beam, together 
with the high frequency of the laser pulse, has rendered MALDI the most widely 
used ionization method for imaging.  The duty cycle of a modern TOF analyzer is 
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an ideal match for the pulsed laser process and also has the advantage of a 
theoretically unlimited mass range, high ion transmission efficiency, multiplex 
detection capability and simplicity in instrument design and maintenance 12.   
A brief description of a MALDI-TOF MS experiment follows for those who 
are not currently practitioners and who seek introductory information; more 
detailed information can be found in other works 13, 14.  A typical analysis of 
proteins directly from tissue is described for illustrative purposes.  Two main 
experimental approaches may be used: profiling and imaging.  Profiling involves 
analyzing discrete areas of the tissue sections and subjecting the resulting 
protein profiles to computational analysis.  These experiments are designed to 
make comparisons between representative areas on a single piece of tissue, 
such as a normal healthy area versus a diseased area, or between two different 
specimens.  A sufficient number of areas must be sampled to gain statistical 
confidence in the results; the number varies depending on the specific 
experiment.  On the other hand, imaging requires that the entire tissue section be 
analyzed through an ordered array of spots, or raster, in which spectra are 
acquired at intervals that define the image resolution (e.g.  every 50 μm in both 
the x and the y direction).  Two-dimensional ion-intensity maps, or images, can 
then be created by plotting the intensities of any signal obtained as a function of 
its xy coordinates.  The resulting images allow rapid assessment of protein 
localization differences between and among samples. 
Tissues used for analysis should be frozen in liquid nitrogen immediately 
after resection to preserve the morphology and minimize protein degradation 
6 
 
through proteolysis.  The tissue is usually sectioned in a cryostat to give 10-15 
μm thick sections and thaw-mounted onto an electrically conductive sample plate 
13.  Sample plates include gold-coated or stainless steel metal plates and glass 
slides that have a conductive coating.  For protein analysis, the tissue section 
may be gently rinsed with ethanol as a fixative and a wash to remove lipids and 
salts.  Alternatively, IMS-compatible tissue-staining protocols can be used in 
conjunction with the optically transparent glass slides, allowing correlation of IMS 
data with histological features of the same section by optical microscopy 15. 
MALDI IMS requires the application of energy-absorbing matrix.  The 
matrix is typically a small organic molecule that co-crystallizes with the analytes 
of interest on the tissue surface.  The matrix is capable of absorbing laser 
energy, thereby causing the analyte to desorb intact from the sample surface and 
ionize.  The most commonly used matrices include 3,5-dimethoxy-4-hydroxy-
cinnamic acid (SA), 2,5-dihydroxybenzoic acid (DHB), 2,5-
dihydroxyacetophenone (DHA), and α-cyano-4-hydroxycinnamic acid (CHCA).  
Solvent combinations and the matrix used will vary depending on the type of 
molecule and tissue being investigated 13.  A 50:50 – 70:30 (v/v) of 
acetonitrile/water or ethanol/water mixture is generally recommended for use in 
protein and phospholipid analyses 16, 17.  SA is an excellent matrix for the 
analysis of proteins 13, DHB, DHA and HCCA are primarily used for the analysis 
of phospholipids, peptides and lower molecular weight analytes.   
For high resolution imaging, the matrix solution should be homogenously 
deposited across the tissue section in such a manner as to avoid significant 
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lateral migration of analytes.  Currently, this is achieved by applying matrix 
solution to the tissue in either a spotted array or a homogenous spray coating 13.  
A continuous and homogenous spray coating allows the highest spatial 
resolution, but densely spotted arrays show higher reproducibility and generally 
better spectra quality.  Heterogeneous matrix coating gives rise to hot and cold 
ablation spots due to random crystal formation, thus producing poor, highly 
pixilated images.  Several robotic spotting devices are commercially available 
and utilize acoustic 18, piezoelectric 19, inkjet printer 20, and capillary deposition 
techniques 21.  Several robotic spray coating devices are also commercially 
available and utilize a mist nebulizing method 22 or a thermal spray method 23.  
Sublimation of matrix can also be used to produce an even layer of small crystals 
across the tissue section for lipid analysis 24. 
Areas are ablated with an UV laser, typically having a target spot size of 
50-100 µm in diameter.  It is possible to image features smaller than the laser 
beam using an oversampling technique 25.  This technique involves the complete 
ablation of the MALDI matrix coating at each sample position and moving the 
sample target a distance less than the diameter of the laser beam before 
repeating the process. 
Protein analysis is usually performed on a linear TOF instrument to attain 
the highest achievable sensitivity.  Ions formed and desorbed during the laser 
pulse are extracted and accelerated into the field-free drift region of the TOF 
analyzer.  Ions are usually detected by a multi-channel plate detector and the 
flight time of the various ions is inversely related to their m/z values.  This time 
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measurement is then converted to m/z through appropriate calibration 
procedures.  For the analysis of low molecular weight species; such as, peptides 
and phospholipids, an ion mirror or reflectron can be used in the ion flight path to 
compensate for the initial velocity/energy distribution and improve resolution 26.   
Instruments utilizing MALDI Fourier transform ion cyclotron resonance 
(FTICR) 27, 28 and MALDI ion trap 29, 30 technologies can be advantageous in the 
analysis of lower molecular weight species.  MALDI FTICR technologies offers 
10–100 times higher mass resolution and mass accuracy than any other mass 
analysis technique 31.  MALDI ion trap technologies allow for coupling tissue 
imaging to tandem MSn enabling concurrent molecular identification 29.  Other 
analyzer combinations have been used with MALDI IMS including TOF-TOF 19, 
orthogonal TOF and orthogonal Quadrapole-TOF (Q-TOF) 32, 33, and ion mobility 
34.  Although it is beyond the scope of this section to describe these in more 
detail, the reader is referred to other works for more thorough descriptions of 
these mass spectrometry technologies 6, 19, 27, 29, 32-34. 
 
I.B.ii.  Reproducibility 
To assess changes in protein concentrations in a given tissue, pixel-to-
pixel reproducibility must be high, that is, two pixels close together having the 
same protein concentrations should give the same spectra within acceptable 
standards.  Although these standards vary from experiment to experiment, 
typically variations of ±15% (or less) are deemed acceptable.  Factors directly 
affecting this aspect of the analysis include ionization efficiency of a given 
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molecule, ion suppression effects, extraction efficiency of the matrix deposition 
process and the robustness and effectiveness of post acquisition processing.  
High pixel-to-pixel reproducibility can be achieved if careful attention is paid to 
sample preparation and matrix application.  In addition, instrument parameters 
such as voltage settings and laser power must be kept constant within an 
experiment.  A robotic matrix application device is invaluable in removing 
operator to operator variations.  In a recent study of protein distribution in brain, 
relative standard errors of 3.7–9.6% were obtained between striatal regions in 
multiple animals 32.  Nevertheless, one must keep in mind that because ionization 
processes can be affected by the physical and chemical processes of molecules, 
it is difficult to estimate relative concentrations of two completely different 
proteins by comparing their peak heights alone. 
 
I.B.iii.  Data Processing and Analysis 
To assess reproducibility, one must perform two general types of data 
analysis: pre-processing and statistical analysis.  The pre-processing step 
reduces the experimental variance between spectra through the removal of 
background, normalization of the peak intensity to the total ion current, and peak 
alignment algorithms.  Normalization of the spectra minimizes variation arising 
from day-to-day instrument fluctuations, differences in matrix crystallization 
across tissue sections, and changes in sample preparation and chemical 
properties of the underlying tissue 35.  Various algorithms are employed for all of 
the spectra processing steps; baseline subtraction, peak alignment, 
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normalization and peak picking.  Ion images are generated directly from these 
processed data sets.   
The next phase of data processing involves downstream events such as 
calculation of average spectra for each specimen type or targeted area in the 
tissue (as determined by the investigator) and subsequent statistical analysis 
procedures.  Principle Component Analysis (PCA) can be performed to reduce 
the dimensionality of a data set using processes to extract, display and rank the 
variance within a data set.  By identifying patterns in data, the investigator can 
more easily determine similarities and differences 36.  Significance Analysis of 
Microarrays (SAM) can be performed to assign a score to each feature on the 
basis of change in its spectral intensity relative to the standard deviation of 
repeated measurements.  For features with a score greater than a predetermined 
threshold, SAM uses permutations of the repeated measurements to estimate 
the percentage of features identified by chance, the false discovery rate (FDR) 37.  
This algorithm is used to elucidate features that change significantly between two 
groups of specimens.  A hierarchical clustering analysis (HCA) may also be 
applied to the data set, enabling samples to be grouped blindly according to their 
expression profiles.  HCA functions by calculating the dissimilarity between the 
individual analyses 38. 
 
I.B.iv.  Biological Applications of IMS 
Over the past decade, proteomics has become a vital complement to 
genetic analysis in the investigation of nearly all aspects of the life sciences 
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including elucidation of cellular processes in both health and disease 39-41, and 
the evaluation of pharmaceutical compounds 42-47.  Lipidomics has gained 
interest in the scientific community because lipids have been found to have 
unique biological roles distinct from their function as a source of energy or as a 
simple construction unit of a membrane.  Mass spectrometry has emerged as an 
important analytical tool for the investigation of these molecules.  In particular, 
MALDI IMS provides the investigator with the ability to analyze the spatial 
distribution of proteins and phospholipids directly in tissue specimens.   
 
I.B.iv.a.  Molecular Images of Disease 
Considerable effort has been focused on finding molecular markers as 
early indicators of disease.  MALDI IMS provides a means to visualize 
molecularly specific information while maintaining spatial integrity.  For example, 
cancer progression is dependent on essential characteristics such as: self-
sufficiency in growth signals, insensitivity to growth-inhibitory signals, evasion of 
apoptosis, high replicate potential, sustained angiogenesis, and tissue invasion 
and metastasis 48.  Alterations in protein expression, proteolytic processing and 
post-translational modifications all contribute to this cellular transformation.  IMS 
analyses of tissue sections reflect the overall status of the tissue, therefore, 
analyses of tissues in various states can reveal differences in the expression of 
proteins which otherwise could not be predicted.  IMS has been used to image 
protein distributions in multiple types of cancer.  Imaging analysis has been use 
to probe proteome changes in mouse breast and brain tumor 49, 50, glioblastoma 
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biopsies 16, human lung metastasis to the brain 51, and prostate cancer 52, 53.  
Identifying features that display differential expression patterns between 
cancerous and normal tissue can provide valuable insight into the molecular 
mechanisms of cancer, provide molecular diagnostic and prognostic signature, 
and identify possible drug targets in implicated pathways. 
Three-dimensional MALDI IMS was first reported in 2005 for the analysis 
of myelin basic protein isoform 8 in the corpus callosum of a mouse brain 54 and 
more recently, it was used to explore three-dimensional protein volumes in the 
substantia nigra in a mouse model of Parkinson’s disease 55.  The acquisition of 
three-dimensional molecular images also raises the exciting possibility of 
combining these MS images with Magnetic Resonance Imaging (MRI) and 
perhaps Positron emission tomography (PET) imaging, so that the molecularly 
specific MS data could be co-registered with these complementary imaging 
technologies.  MRI technology relies on the relaxation properties of excited 
hydrogen nuclei in water and lipids after exposure to a powerful, uniform 
magnetic field 56.   
Figure 3 shows the results of experiments wherein IMS and MRI were 
combined to analyze a mouse brain injected with glioma cells and to visualize the 
data in three dimensions 9.  The entire mouse head was sectioned from the 
olfactory bulb to the beginning of the spinal cord.  Coronal sections of the mouse 
brain were collected at 20 μm increments as a high-resolution camera acquired 
blockface images every 40 μm.  Tissue sections for IMS analysis were collected 
every 160 μm, coated with SA and imaged at 150 μm lateral resolution.  In 
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Figure 3 (right), Histone H2B, is associated with the tumor as it manifests in the 
contra-lateral ventricle.  Conversely, in Figure 3 (left), the myelin basic protein 
isoform 4 image demonstrates that the corpus callosum can be accurately 
spatially correlated in a three-dimensional sample-specific context.  A good 
correlation of the tumor between MALDI ion intensities, contrast variation in the 
magnetic resonance parameters, and the optical volume were observed. 
IMS has also been utilized to study neurodegenerative diseases such as 
Alzheimer’s and Parkinson’s.  Neurodegeneration is widespread in Alzheimer’s 
disease, affecting several brain regions.  ß-Amyloid plaques accumulate causing 
plaque formation and subsequent neurodegeneration 57, 58.  A mutation of the 
amyloid precursor protein gene causes a higher production of ß-amyloid and ß-
amyloid peptides in the cortical and hippocampal structures of the brain.  MALDI 
images showed that the ß-amyloid peptides (1-40) and (1-42) were the most 
abundant amyloid peptides in those brain regions in an Alzheimer’s disease 
mouse model 59.   
From previous studies of Parkinsonism, a condition that affects regions of 
the brain that control motor function (such as the substantia nigra and the 
striatum), it was found that dopamine neurons in the nigrostriatal pathway are 
gradually decreased in the striatum.  IMS technology has been applied to the 1-
methyl 4-phenyl 1,2,3,6-tetrahydropyridine (MPTP) animal model of 
Parkinsonism 60; the investigators found that purkinje cell protein 4 (PEP-19), a 
neuronal calmodulin-binding protein, was significantly reduced (by 30%) in the 
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striatum compared to control regions in normal brain.  Further study is needed to 
determine the specific involvement of PEP-19 in neurodegeneration. 
 
I.B.iv.b.  Proteome Response to Drug Administration 
In addition to assisting in disease differentiation and diagnosis, the 
proteome signature of a tissue can also be used for determining the effects of 
drug/small-molecule administration to an animal model or patient.  Over the past 
decade, proteins have become principal targets of drug discovery, and 
proteomics-oriented drug research has come to the forefront of activity in this 
area.  Proteomics plays a major role in drug development, specifically in target 
identification, target validation, drug design, lead optimization, and pre-clinical 
and clinical development 61.   
Pharmaceutical drug discovery is a laborious and tedious process: it can 
take from 8 to 10 years, at great expense, to bring a drug candidate onto the 
market 42.  Obviously, it is essential to find ways to expedite this process.  With 
the early assessment of the distribution of a drug candidate in targeted tissues, 
IMS can greatly assist in the discovery and validation of  processes related to 
drug administration, distribution, metabolism and excretion (ADME) 62, 63.  For 
example, IMS can individually detect the presence and location of an individual 
drug and its metabolites in a label-free protocol, a significant advantage over 
other small molecule imaging techniques that typically require the addition of a 
radioactive tag to the molecule of interest, such as in autoradiography.  Another 
advantage of IMS is that it is capable of providing information on both the 
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pharmacological and biological effects of a drug in that it can detect molecular 
features that may be markers of drug efficacy or toxicity.  Other imaging 
techniques give little information on the molecular identity of these biological 
endpoints.  Thus, IMS can monitor the analyte of interest and also the 
corresponding proteome response.  For example, investigators have discovered 
transthyretin as a marker for gentamicin-induced nephrotoxicity in rat 11.  
Gentamicin-induced nephrotoxicity is seldom fatal and is usually reversible but 
often results in long hospital stays.  Thus, there is great interest finding potential 
markers of early toxicity and also to help elucidate the molecular mechanism.  
Investigators utilized MALDI IMS to determine differential protein expression 
within the rat kidney (cortex, medulla, and papilla), identified features of interest 
between dosed and control rat, and then applied downstream protein 
identification procedures.  Transthyretin signal was significantly increased in the 
treated mouse kidney over control and these findings were validated with 
western blot and immunohistochemistry.   
To study the relationship between the drug distribution in tumors and the 
resulting protein alterations, mass spectral images were obtained from 
MMTV/HER2 tumors excised from mice 50.  Investigators were able to identify 
markers that indicate a response of the tumor to administration of erbB receptor 
inhibitors OSI-774 and Herceptin.  Inhibition of tumor cell proliferation, induction 
of apoptosis, and tumor reduction were predicted by a >80% reduction in 
thymosin ß4 and ubiquitin levels that were detectable after 16 hours of a single 
drug dose before any evidence of in situ cellular activity.   
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These same procedures discussed for excised organs or tumors can also 
be applied to whole-body animal tissue sections for a system-wide analysis in a 
single experiment 32.  For whole-body sagittal tissue sections, using the same 
sample preparation and analysis conditions described for IMS experiments of 
tissues, signals unique to individual organs were detected and used to produce a 
two-dimensional protein map of a control rat (Figure 4).  By expanding the 
capabilities of MALDI IMS to investigate multiple tissue types simultaneously 
across a whole-body tissue section, distinct protein patterns can be identified and 
used to monitor whole-body systems dynamics. 
 
I.B.iv.c.  In situ Proteomics 
Because the MALDI desorption process leads to the measurement of the 
molecular weight of a given protein, off-line techniques involving extraction, liquid 
chromatographic (LC) separation, digestion and LC-MS/MS analyses with 
database searches are performed to identify a protein.  These approaches are 
effective, but are very time consuming and costly.  Direct in situ protein 
identification provides a significant advantage in such cases.  Investigators have 
developed a protocol that allows digestion of proteins directly on thin tissue 
sections using well defined microspotted arrays of enzymes that can 
subsequently be spotted with matrix for IMS and MALDI MS/MS analyses 19.  
Although any enzyme can be used, the serine protease, trypsin, is the most 
common choice because it has a very well defined specificity in that it 
preferentially hydrolyzes the peptide bond at the carboxyl side of the amino acids 
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lysine (K) and arginine (R).  In one such study (Figure 5); trypsin spots (150 µm 
diameters) were deposited in an array (spots located 200 µm apart) on a section 
of mouse brain.  For two specific proteins, neurogranin and PEP-19, four tryptic 
peptides from each were identified and sequenced by MALDI MS/MS directly 
from the tissue digest spots.  The image of each peptide was then constructed 
(Figure 5). 
The application of IMS to the analysis of formalin-fixed paraffin embedded 
(FFPE) tissue sections has also been undertaken.  FFPE is the most convenient 
method to preserve samples in hospital tissue banks; this method is of great 
interest as millions of tissue samples are stored worldwide, many of which are 
linked to detailed patient histories and outcomes.  However, analysis of the 
proteins in formalin fixed tissues is a major challenge: the fixation process alters 
the structures of the proteins by cross-linking, thereby changing the molecular 
weight, often in unpredictable ways.  Recent studies have focused on protocols 
utilizing antigen retrieval, in situ trypsin digestion and subsequent IMS analysis to 
analyze such samples and thus far have shown promise.  For example, IMS was 
used to analyze a two-year-old archived FFPE rat brain tissues and the results 
showed the same localization of various proteins as that of the proteins within 
frozen tissue sections 64.   
Preserved FFPE tissues are often collected into tissue microarrays, which 
consist of paraffin blocks in which hundreds of separate tissue cores are 
assembled in array fashion to allow simultaneous histological analysis.  In one 
study, microarray FFPE tissues, containing 112 needle core biopsies from lung-
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tumor patients, were analyzed by IMS following antigen retrieval and on-tissue 
tryptic digestion protocols 65.  This high-throughput approach allows investigators 
to detect and characterize tumor marker proteins from a large cohort of 
microarray samples. 
 
I.B.iv.d.  Phospholipid Imaging 
MALDI IMS has been used to analyze glycerophospholipids, phosphate-
containing glycerol-based lipids, which are the main component of biological 
membranes.  The major classes of these phospholipids, grouped according to 
the headgroup identity, are phosphatidylcholine (PC), sphingomyelin (SM), 
phosphatidylinositol (PI), phosphatidylserine (PS), phosphatidylglycerol (PG) and 
phosphatidylethanolamine (PE).  Many molecular species exist within each class 
containing different combinations of fatty acids in the sn1 and sn2 position of the 
glycerol backbone.   
Several MALDI IMS studies have focused on mapping phospholipid 
distributions in brain tissue sections 17, 66-69.  Lipids are one of the most abundant 
biomolecules found in the brain, second only to water.  Lipids make up 50% of 
the dry weight of the brain and play an important role in brain anatomy, 
physiology and pathophysiology.  Altered levels of phospholipids are associated 
with Farber disease, Gaucher disease, Niemann-Pick disease, Alzheimer 
disease, and Down syndrome 70-73.  IMS analysis of rat brain sections found PI 
38:4 and PC 36:1 localize mainly to the gray matter, conversely, PC 32:0 
localizes mainly to the white matter 74.  This inverse relationship between PC 
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36:1 and PC 32:0 was documented in another IMS study and the corresponding 
images are depicted in Figure 6 7.  Although, these IMS results are supported by 
earlier studies 75 to begin to understand the biology implications of these images 
each fatty acid chain needs to be identified.  This will be discussed more in 
Chapter III, where phospholipid fatty acid chains were identified directly from 
mouse implantation site tissue sections by FTICR and Tandem MS analyses.   
MALDI IMS has an advantage over thin-layer chromatography (TLC) and 
LC-Tandem-MS, in that, the anatomical integrity of the sample is maintained.  
TLC and LC-Tandem-MS techniques require homogenization prior to lipid 
analysis 76, 77.  Immunostaining of the phospholipid head group can be used to 
obtain spatial information on phospholipids, but this technique cannot distinguish 
between the unique molecular species for each phospholipid class 78.  Imaging 
mass spectrometry can visualize the spatial distribution of different phospholipid 
species (e.g.  same headgroup different fatty acid chains [Figure 6]).   
In addition to MALDI-MS, other mass spectrometric techniques such as 
desorption electrospray ionization mass spectrometry (DESI) 79 and secondary 
ion mass spectrometry (SIMS) 8, 80, 81 have also been used for lipid imaging 
studies.  New technologies, such as, MALDI-ion mobility-TOF MS imaging with 
gold nanoparticles as matrices enabled low abundant cerebroside species to be 
imaged in a rat brain section 82.  Cerebroside cannot be seen with traditional 
MALDI IMS methods because they are suppressed by the highly abundant PC 
which account for approximately 50% of phospholipid mass in cell membranes 83, 
84.  In another study, tandem Imaging MS was successfully used for the structural 
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characterization of isobaric PCs, PEs, PSs and DHB clusters while maintain the 
spatial localization of each species 66.  Overall, technological advancements in 
IMS has allowed for sensitive and very selective analyses of lipids with diverse 
chemical compositions, therefore, advancing the lipidomics field in biomedical 
research 85.   
 
I.B.iv.e.  New Insights into Biology 
MALDI IMS of tissue sections can provide information on the spatial and 
temporal action of proteins involved in processes that take place in organs or 
tissue substructures that contain heterogeneous cell types.  A major advantage 
of MALDI IMS is that it allows the investigator to visualize molecular events while 
retaining spatial information that would have been lost using techniques that 
require tissue homogenization and extraction. 
In a project involving mammalian reproduction 86, investigators evaluated 
protein expression during normal mouse prostate development (1-5 weeks of 
age), at sexual maturation (6 weeks of age), and in adult prostate (at 10, 15, or 
40 weeks of age) 53.  This same study compared temporal protein expression in 
the prostate between healthy mice and mice with prostate tumors (LBP-Tag 
mouse model for prostate cancer).  The expression of probasin and spermine-
binding proteins was significantly decreased in prostate tumor formation.  
Cyclophilin A was differentially α-acetylated on the n-terminus, during normal 
prostate and prostate tumor development.  In summary, tissue profiling and 
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imaging were able to identify proteins related to prostate morphogenesis and 
tumorigenesis.      
 
I.C.  Summary and Research Objectives 
Due to the fact that there is a high degree of molecular complexity in 
biological systems, new tools are needed to elucidate molecular events in both 
spatial and temporal distributions.  IMS provides unique information of peptides, 
proteins and phospholipids directly from complex tissue surfaces, bringing 
powerful new capabilities to biological research.  IMS requires relatively easy 
sample preparation and is well suited to high-throughput analysis (on the order of 
seconds per sample).  Most importantly, it is an excellent discovery tool in 
research, providing that the analytes investigated do not need to be known in 
advance.  Hundreds of signals can be extracted from a single experiment with 
relatively high mass measurement accuracy.  Because the spatial integrity of the 
tissue is maintained, molecular images and patterns can easily be correlated with 
histopathological analyses. 
The objective of our analysis was to use IMS to investigate the 
mammalian reproductive process involving implantation and early development 
of the embryo.  The heterogeneous cell types of the uterus, each with unique 
function, pose a challenge for studying events during early pregnancy.  In 
rodents and humans, one of the limiting factors is the availability of adequate 
amounts of tissues for biochemical and molecular biology experiments.  Studying 
the uterine molecular landscape using conventional approaches presents an 
arduous task since some molecules localize to particular cell types on a specific 
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day of pregnancy and do not reappear later in the process.  Disregulation of 
events prior to, during, or immediately after implantation contributes to poor 
pregnancy rates.  Therefore, understanding molecular localization patterns 
during implantation is essential to provide potential targets for treating infertility 
and developing novel contraceptive approaches. 
In preliminary IMS experiments, we studied implantation sites from mice 
on day 6 (D6) and day 8 (D8) of pregnancy and obtained molecular distributions 
that were unique to embryo, surrounding muscle and uterine stroma within an 
area measuring ≤3 mm2.  The ion-intensity maps presented in Figure 7 illustrate 
the power of IMS in viewing how molecular location and expression changes 
during early pregnancy.  The ions depicted in red and green are expressed in the 
presence of the embryo only on D6 through D8 of pregnancy.  The ion shown in 
red is expressed at the site of the embryo and increases by D8.  The uterus has 
two poles; the mesometrial pole (M), where the blood supply enters the uterus, 
and the antimesometrial pole (AM), where the embryo implants.  The ion 
depicted in purple remains at the AM pole in these images, whereas the ion 
depicted in green shifts solely to the AM pole by D8.  The ion shown in blue 
represents the muscle surrounding the uterus.  The correlation of molecular 
information to anatomical structures in implantation sites offers tremendous 
potential for a better understanding of biological processes essential to embryo 
implantation. 
Briefly, in Chapter II we detail the cellular events associated with mouse 
embryo implantation.  In Chapter III & IV we explore phospholipid and protein 
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localization on days 4-8 of mouse pregnancy, respectively.  In Chapter V, we 
analyze the expression of these molecules in context with the cellular 
transformations of the uterus and the embryo.  From this analysis we found that 
small structural changes in phospholipids have a huge impact on the biological 
activity and distribution across the implantation sites.  Also, biological processes 
essential to embryo implantation are highly regionalized and take place in very 
discrete time domains.   
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CHAPTER II 
 
STAGES OF MOUSE EMBRYO IMPLANTATION 
 
Establishment of a receptive uterus to support embryo development and 
implantation depends on coordinated effects of ovarian steroid hormones 
estrogen and progesterone (P4) 2.  Studies in mice using embryo transfer 
experiments have shown that uterine receptivity occurs for a limited period during 
pregnancy: the prereceptive uterus on days 1-3 becomes receptive on day 4 and 
nonreceptive by late day 5 of pregnancy 87.  In mice, implantation sites are evenly 
spaced with implantation and interimplantation sites differing in molecular 
composition, the former influenced by the embryo and the latter without such 
influence.  Once implantation occurs on the evening of day 4 of pregnancy, the 
uterine stroma surrounding the embryo at the implantation site undergoes 
extensive remodeling, a process termed decidualization.  Thus, it is highly 
expected that differential molecular signatures are represented not only by 
implantation and interimplantation sites, but also by the cellular regions within 
these sites. 
The initial attachment reaction between the embryo and the luminal 
epithelial cells lining the inside of the uterus occurs approximately between 2200 
– 2300 h on day 4 of pregnancy (vaginal plug = day 1).  This attachment is 
accompanied by an increased endometrial vascular permeability at the sites of 
blastocysts, which can be visualized as distinct blue bands after an intravenous 
injection of a Chicago Blue dye solution 88.  This blue dye method is a useful tool, 
since implantation and interimplantation sites can be separately excised, and 
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sections with and without the implanting embryo can be obtained for differential 
characterization.  Figure 8 shows day 5 and 6 mouse uteri with blue bands 
(implantation sites) along with resulting implantation site sections.  On day 8 of 
pregnancy, blue dye injection is not necessary, since implantation sites are larger 
and visually distinguishable (Figure 8).  Following the attachment reaction, in a 
process termed luminal closure, the inner canal of the uterus collapses in on 
itself resulting in an intimate apposition of the embryo with the luminal epithelium 
89, 90.  This luminal closure reaction is evident in the day 5 implantation site 
section of Figure 8 since all that remains of the inner canal is a thin line of 
luminal epithelium cells which stretch from the embryo to the Mesometrial Pole.  
On the afternoon of day 5 of pregnancy, the proliferating stromal cells bordering 
the implanting embryo begin to differentiate into decidual cells, forming the 
avascular primary decidual zone (PDZ).  By day 6, the PDZ completes 
differentiation, and a secondary decidual zone (SDZ) forms around the PDZ.  
Although proliferation is terminated in the PDZ, it continues in the SDZ.  The PDZ 
then progressively degenerates through day 8 of pregnancy.  On day 8 of 
pregnancy the SDZ decidual cells surrounding the embryo at the antimesometrial 
(AM) pole undergo apoptosis to create space for the growing embryo; whereas, 
the region containing decidual cells at the mesometrial (M) pole undergoes 
angiogenesis forming a vascularized zone that brings maternal and fetal blood 
vessels in close proximity, a prerequisite for the formation of a functional 
placenta 2.  This maternal-fetal interface is achieved by rapid multiplication of 
33 
 
embryonic trophoblast cells towards the M pole, resulting in the formation of an 
ectoplacental cone (EPC) by day 8 of pregnancy.   
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CHAPTER III   
 
DETECTING SPATIAL AND TEMPORAL DISTRIBUTIONS OF 
PHOSPHOLIPIDS DURING EMBRYO IMPLANTATION BY MALDI 
IMAGING MASS SPECTROMETRY 
 
A.  Overview 
Molecular events involved in successful embryo implantation are not well 
understood.  In this study, we used MALDI Imaging Mass Spectrometry 
technologies to characterize the spatial and temporal distribution of phospholipid 
species associated with mouse embryo implantation.  Molecular images showing 
phospholipid distribution within implantation sites changed markedly between 
distinct cellular areas during days 4-8 of pregnancy.  For example, by day 8, 
linoleate- and docosahexaenoate-containing phospholipids localized to regions 
destined to undergo cell death, whereas oleate-containing phospholipids 
localized to angiogenic regions.  Arachidonate-containing phospholipids showed 
different segregation patterns depending on the lipid class, revealing a strong 
correlation of phosphatidylethanolamines and phosphatidylinositols with cytosolic 
phospholipase A2α and cyclooxygenase-2 during embryo implantation.  Liquid 
chromatography-electrospray ionization tandem MS was used to validate MALDI 
IMS phospholipid distribution patterns.  Overall, molecular images revealed the 
dynamic complexity of lipid distributions in early pregnancy, signifying the 
importance of complex interplay of lipid molecules in uterine biology and 
implantation. 
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B.  Introduction 
There is evidence that phospholipid metabolism and signaling influences 
early pregnancy events 91.  Phospholipids are vital structural and regulatory 
components of biological membranes and serve as precursors for many active 
biomolecules, such as eicosanoids and lysophospholipids 92, 93.  Prostaglandins 
(PG), one major group of eicosanoid lipid molecules, are produced from 
arachidonic acid (AA) that is released from membrane phospholipids by 
phospholipase A2 (PLA2).  The released AA is acted upon by cyclooxygenases 
(COX) to form PGH which is then converted to various PGs by specific PG 
synthases 94.  Spatiotemporal expression profiles of cytosolic PLA2α (cPLA2α), 
COX-1 and COX-2 in the uterus at different stages of pregnancy suggest their 
differential functions 95-98.  In mice, PGI2 and PGE2 generated by COX-2 are 
essential for ovulation, fertilization, implantation and decidualization 96, 97, 99-102.  
PG’s role is further illustrated by poor fertility, resulting from deferred 
implantation, in mice lacking cPLA2α 95.  Another example for critical roles of lipid 
signaling in reproduction is the influence of lysophosphatidic acid (LPA), a small 
lipid molecule of the lysophospholipid family.  LPA influences a variety of 
processes via its cell-surface G protein coupled receptors, LPA1-4 103.  In mice, 
LPA3 is expressed in the uterine luminal epithelium with peak expression 
occurring during the periimplantation period, and its expression overlaps with 
cPLA2α and COX-2 at the site of implantation 104.  More importantly, mice missing 
LPA3 show remarkably similar defects as cPLA2α-deficient mice, such as deferred 
on-time implantation, retarded fetal development, embryo crowding, and sharing 
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of one placenta by several embryos 95, 104.  Restoration of on-time implantation in 
LPA3-deficient females by PG supplementation suggests an intimate interaction 
between the LPA-LPA3 and cPLA2α-COX-2-PG signaling pathways 104.  These 
findings established a new concept that a short delay in the attachment of 
blastocysts to the uterine lining during early pregnancy creates adverse ripple 
effects during the subsequent course of pregnancy, ultimately compromising 
pregnancy outcome 91, 105, 106.  There is also evidence that disturbances in 
sphingolipid metabolism by disruption of sphingosine kinase genes causes 
sphingoid base accumulation and a reduction of phosphatidylethanolamines, 
thereby inducing early pregnancy loss by compromising decidualization and the 
uterine vascular bed stability 107.   
The goal of the present study was to utilize mass spectrometry 
technologies to assess globally the differential distribution of 
glycerophospholipids and sphingomyelins during the cellular events that define 
implantation.  We speculate that spatial distribution of those phospholipids plays 
important roles in the implantation process.  Matrix-Assisted Laser 
Desorption/Ionization Imaging Mass Spectrometry (MALDI IMS) generates ion 
density maps from tissue sections that allow protein and phospholipid localization 
to be visualized without prior knowledge of the specific molecules being analyzed 
66, 67, 79, 81, 108-112.  This technology has been previously used to analyze proteins 
involved in proliferation, differentiation and apoptosis during early mouse 
pregnancy, providing unique and distinctive proteomic profiles of implantation 
sites 113.  In the present study, phospholipid distribution was visualized using the 
38 
 
molecular imaging mode of both MALDI-TOF/TOF (TOF, Time-of-flight) and 
MALDI Fourier Transform Ion Cyclotron Resonance (FTICR) mass 
spectrometers.  The fatty acid chain identities for each phospholipid were 
determined by tandem mass spectrometry (MS/MS) fragmentation.  Isobaric 
phospholipid species with identical masses were visually distinguished using the 
MS/MS imaging mode of a MALDI linear ion trap (LTQ) mass spectrometer.  
Finally, absolute quantitation and identification of phospholipids on day 8 of 
pregnancy was determined using liquid chromatography-electrospray ionization 
tandem MS (LC-ESI-MS/MS) with odd carbon internal standard in order to further 
validate phospholipid distribution patterns obtained from the MALDI MS images. 
 
C.  Results 
C.i.  Spatial remodeling of phospholipids during early pregnancy.  The 
molecular images obtained in this study show that phospholipid distributions 
correlate with the heterogeneous cell types (indicated in Figure 8) that arise 
during the course of implantation.  Zwitterionic phosphatidylcholines (PCs) and 
sphingomyelins (SMs) are readily detected in the positive mode (Figure 9) by 
MALDI MS; whereas, the anionic phosphatidylinositols (PIs), phosphatidylserines 
(PSs), and phosphatidylglycerols (PGs) are best detected in the negative mode 
(Figure 10).  Phosphatidylethanolamines (PEs) and phosphatidylethanolamine 
plasmalogens (PEps) can be detected as positive or negative ions, but are 
usually best measured in negative mode directly from tissue sections.   
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Images of specific phospholipids taken during day 4-8 are shown in 
columns in Figures 9 and 10.  At the top of each column phospholipids are 
labeled using accepted lipid nomenclature where the first number represents the 
total number of carbon atoms in the two fatty acid chains, and the second 
number represents the total number of double bonds in the two fatty acid chains.  
The identity of each individual fatty acid side chain is located in parenthesis 
(sn1/sn2).  Fatty acid chains were identified from a combination of the exact 
mass of the phospholipid molecular species and the MS/MS fragmentation 
pattern (described below).   
From these data, phospholipid expression patterns can be categorized 
according to the degree of unsaturation of the sn2 fatty acid chain.  
Consequently, the images displayed in Figures 9 and 10 are aligned in 
increasing order of unsaturation; 16:0, 18:0, 18:1, 18:2, 20:4, 22:4, and 22:6.  
Although there remains some uncertainty in the sn1 and sn2 positional 
assignment of fatty acids from mass spectral data, it is generally accepted that 
the more unsaturated fatty acids occupy the sn2 position.  Table 1 and Table 2 
list fragment peaks from highest intensity to lowest intensity 67, 114.   
The molecular images shown in Figures 9 and 10 depict alterations in 
phospholipid distributions as uterine cells undergo decidual changes from day 4 
to day 8 of pregnancy.  Before embryo attachment, luminal epithelial cells show 
substantial increases for SM 16:0 and PCs with 18:1, 18:2 and 20:4 as their 
unsaturated fatty acid chain (Figure 9).  Conversely, PC (16:0/16:0) shows 
relatively higher expression in all cell types except for the luminal epithelial cells.  
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Overall, this saturated phospholipid shows an inverse localization pattern when 
compared to the other phospholipids on days 4-8 of pregnancy.  On day 5 of 
pregnancy, glycerophospholipid images show an intensity increase in uterine 
stroma cells at the site of embryo attachment, whereas on day 6, 
glycerophospholipid expression is most intense in the PDZ.  Also, certain 
phospholipids show higher levels in the M pole (above the embryo in these 
images) and AM pole (around the bottom of the embryo).  Higher expression in 
the M pole is seen for all PC (16:0/18:1), PE (16:0/18:1), and PI (18:1/20:4), 
whereas higher expression at the AM pole can be seen for PC (18:0/18:2) and PI 
(16:0/18:2).  On day 8 of pregnancy many of the phospholipids show higher 
intensity either in the M pole or AM pole.  Overall, the phospholipids that show 
higher levels at the M pole are: PCs, PE, PG and PS containing 18:1; PIs and PE 
with 20:4 as their polyunsaturated fatty acid; and PEp (16:0/22:4).  The 
phospholipids showing higher intensities at the AM pole are: PCs, PIs, and PS 
having 18:2 as a substituent; PCs with 20:4 as their polyunsaturated fatty acid; 
PC, PEp, and PI with 22:6 as their polyunsaturated fatty acid.  The reproducibility 
of these results is represented in Figures 11, 12 and 13, and the quality of the 
primary Maldi Spectra is represented in Figure 14 (positive ion mode) and 
Figure 15 (negative ion mode).  Subsequent experiments were focused on the 
day 8 implantation sites, because the most dramatic spatial changes in 
phospholipid expression were observed.  Day 8 implantation sites also contain 
major cellular alterations including angiogenesis, apoptosis and proliferation. 
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C.ii. Determining the presence of isobaric ions (same nominal mass but 
different exact masses) in day 8 implantation sites by FTICR IMS.  The 
molecular weights of phospholipids investigated in this study are between 600 
and 1000 Da. Within this mass range, the peak density of MALDI spectra are 
typically complicated by a large number of other endogenous metabolites as well 
as matrix ions. Together with the naturally occurring carbon isotopes of these 
species, the resolving power of TOF instruments may not be capable of 
determining if multiple isobaric ions are contributing to a specific ion image. 
Positive ion spectra, in particular, can be quite complex with the possibility of 
detecting ions adducted with H+, Na+ or K+. To determine isobaric interference, 
MALDI images of Day 8 embryos were also acquired on a FTICR at a resolving 
power of 100,000 (FWHM). Peak widths were 10-20 mDa, compared to 100-200 
mDa for the TOF spectra, and are sufficient to resolve most phospholipid species 
that are typically observed in MALDI spectra. Ion images from both instruments 
are shown in Figure 9 and 10 and from these data it is clear that only one 
molecular species contributes to the TOF images.   
An example where multiple isobaric ions were detected is shown in Figure 
16.  Figure 16 illustrates MALDI-TOF images (top) and corresponding MALDI-
FTICR (bottom).  The first 2 columns and last 2 columns represent the 
potassiated (K+) and sodiated (Na+) forms of PC 34:1 (16:0/18:1) and PC 34:2 
(16:0/18:2), respectively.  The TOF images of the potassiated form of each 
phospholipid species do not contain any interfering ions.  Conversely, the TOF 
images of the sodiated form of each phospholipid species represent multiple 
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ions.  The TOF image of PC 34:1 Na+ contains an unknown interfering peak at 
782.509 m/z.  The TOF image of PC 34:2 Na+ contains 3 unknown interfering 
peaks with m/z values 758.508, 758.545, and 758.525.  The FTICR images of 
PC 34:2 Na+ illustrates the strength of this technology, by its ability to spatially 
resolve 4 different ions within a mass window of only 0.06 Daltons.    
 
C.iii.  In situ identification of phospholipids by tandem MS.  Identification of 
fatty acid chains in the phospholipids was accomplished using both the accurate 
mass of the parent phospholipid ion with FTICR IMS (mass accuracy of +/- 0.005 
Da at m/z 1,000 [5 ppm]) and MS/MS fragmentation spectra 115.  Table 1 and 2 
contain the accurate mass and fragmentation peaks for each lipid in positive and 
negative ion mode, respectively.  The structures and fragmentation spectra of PI 
(18:0/18:2) and PC (18:0/18:2) are shown in Figure 17. 
 
C.iv.  Distinguishing spatial distribution of isobaric phospholipids (identical 
masses) in day 8 implantation sites by tandem IMS.  The MS images for 
phospholipids PE 36:2 and PE 38:2 showed no distinct spatial location (Fig 18, 
left). However, MS/MS fragmentation found each of these phospholipid ions to 
consist of multiple isobaric species (structure of each isobar Fig 18, middle). PE 
18:0/18:2 and PE 18:1/18:1 are isobars of the class PE 36:2 (m/z = 742.54).  PE 
20:0/18:2, PE 18:0/20:2, and PE 18:1/20:1 are isobars of PE 38:2 (m/z = 770.57).  
Tandem MS imaging determined the spatial location of each isobar in day 8 
implantation sites (Fig 18, right).  The MS/MS images of PE 36:2 and PE 38:2 
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confirmed that more than one combination of sn1 and sn2 fatty acids were 
present. Although MS/MS images were obtained for each fragment ion, Figure 
18 displays only the most intense fragment ion from each isobar (represented by 
a red arrow on each phospholipid structure). The MS/MS images of PE 36:2 
contain 18:2 (signified by the fatty acid 18:2 or the 279 m/z fragment ion) that 
localized to the bottom (AM pole) and 18:1 (281 m/z fragment ion) that localized 
to the top (M pole) of the day 8 implantation site. The MS image of PE 38:2 
includes PE (20:0/18:2), PE (18:0/20:2), and PE (18:1/20:1). The MS/MS images 
of PE 38:2 contain either the diunsaturated 18:2 fatty acid (279 m/z fragment ion) 
or 18:0 fatty acid (283 m/z fragment ion) that both localize to the AM pole or the 
monounsaturated fatty acid 18:1 (281 m/z fragment ion) that localizes to the M 
pole of the day 8 implantation site. 
 
C.v.  Validation of MALDI IMS phospholipid expression patterns by liquid 
chromatography-electrospray ionization tandem MS (LC-ESI-MS/MS) 
quantitation.  LC-MS/MS was used to quantify and identify phospholipids in the 
M and AM poles on day 8 of pregnancy (Figure 19a-c).  Approximately 15 mg of 
tissue was needed for this analysis; thus, day 8 implantation sites were micro-
dissected (Figure 19a) to isolate the top and bottom hemispheres for subsequent 
organic phase lipid extraction.  The bottom row of Figure 19c contains selected 
FTICR phospholipid images that exhibit the greatest change in relative 
abundance between the M and AM poles in day 8 implantation sites.  LC-MS/MS 
quantitation of these same phospholipids is illustrated as block structures, set to 
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the same linear black and white scale as the MALDI images, in the top row of 
Figure 19c or as bar graphs in Figure 19b.  In summary, LC-MS/MS quantitation 
and MALDI IMS showed excellent agreement, with PC 34:1 (16:0/18:1), PE 34:1 
(16:0/18:1), and PI 38:5 (18:1/20:4) localizing to the M pole and PC 34:2 
(16:0/18:2), PI 34:2 (16:0/18:2), PC 36:4 (16:0/20:4), PC 40:6 (18:0/22:6) and PI 
40:6 (18:0/22:6) localizing to the AM pole.  Table 3 contains all of the statistically 
significant LC-MS/MS results. 
 
C.vi. Colocalization of arachidonate-containing phospholipids with 
cyclooxygenase-2 (COX-2).  Signaling of prostaglandin signaling, resulting from 
cPLA2α-COX-2 processing of arachidonate (20:4), participates in embryo 
attachment and uterine decidualization during embryo implantation 95, 97.  Thus, it 
was of interest to determine which arachidonate-containing phospholipids 
colocalize with COX-2. Figure 20 shows an immunohistochemistry (IHC) stain 
for COX-2 and the MALDI images of arachidonic acid containing phospholipids. 
COX-2 expression localizes to the M pole above the EPC, correspondingly PIs 
and PEs show M pole expression with PE 38:5 (18:1/20:4) and PI 38:5 
(18:1/20:4) exhibiting highest levels of expression above the EPC.  In contrast, 
PC 36:4 (16:0/20:4) and PC 38:4 (18:0/20:4) expression patterns are confined to 
the AM pole. 
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D.  Discussion 
Lipids are important components of cellular membranes and also serve as 
signaling molecules that help coordinate events during embryo implantation and 
postimplantation growth 97, 104. In the present study, we have mapped 
phospholipid distributions during embryo implantation employing the molecular 
specificity of mass spectrometry. The results demonstrate that distribution of 
phospholipids is markedly altered during implantation with changes specific to 
the M (top) and AM (bottom) poles of the uterus, suggesting roles for those 
phospholipids in the implantation process.   
The distribution of phospholipids showed significant changes in day 5 
implantation sites after embryo attachment, and most phospholipids showed 
substantial increases in the stroma immediately surrounding the implanting 
embryo. The spatial redistribution continued on days 6-8 of pregnancy with 
differential localization in the M and AM poles of the implantation sites.  With 
respect to proteins, previous reports on day 8 of pregnancy revealed an 
increased level of proteins involved in angiogenesis at the M pole and those 
involved in cell death at the AM pole. Specifically, pro-angiogenic proteins 
angiopoietins 2 (Ang2) and Ang3 and their endothelial-specific receptor tyrosine 
kinase Tie2 show an increased expression at the M pole, which also expresses 
COX-2, a known enhancer of angiogenesis 2. Although the mechanism(s) 
governing decidual cell death at the AM pole are not clearly understood, there is 
evidence that a balance between proapoptotic Bax and antiapoptotic Bcl are 
involved 116. Regardless, these differential behaviors of the M and AM poles have 
biological significance with respect to increasing angiogenesis at the M pole, the 
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site of angiogenesis, and initiating apoptosis or cell death at the AM pole to make 
room for the rapidly growing embryo.  This molecular orchestration of lipids and 
proteins in both space and time underscores the complex biological processes 
involved in sustaining embryo growth and survival during early pregnancy.  
For lipids, these data show a segregation of phospholipids that contain 
linoleate (18:2) and docosahexaenoate (22:6) at the AM pole, and oleate (18:1) 
at the M pole, across all lipid classes. Arachidonate (20:4) containing 
phospholipids showed differential segregation patterns depending on the lipid 
class. This is interesting in the context of the reported finding that liberation of 
arachidonate by cPLA2α from membrane phospholipids is class-dependent 117, 
118. This may explain why different classes of arachidonic acid containing 
membrane phospholipids show differential expression patterns in our molecular 
images. There is now evidence that COX-2 expressed on day 8 of pregnancy at 
the M pole above the EPC plays a role in angiogenesis 97 (Figure 20). 
Phospholipids that act as substrates in the cPLA2α-COX-2 pathway should co-
localize with the rate limiting enzyme COX-2. In fact, while arachidonate 
containing PEs and PIs are localized to the M pole, arachidonate containing PCs 
are found to be localized to the AM pole. 
The present study reveals the importance of obtaining detailed molecular 
information on both a spatial and temporal basis to uncover the complexity of 
biological events. We believe this paper will initiate further studies which will help 
us to better understand the intricacies of implantation and how specific lipid 
species may mediate, balance, and control cellular events.  
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E.  Materials and Methods 
Mice.  Adult CD-1 mice were purchased from Charles River Laboratory (Raleigh, 
NC).  Females were mated with fertile males of the same strain to induce 
pregnancy.  Mice were sacrificed between 0900 and 1000 h on the specified day 
of pregnancy (0 h on day 1 = vaginal plug).  Implantation sites on days 5 and 6 of 
pregnancy were visualized by an intravenous injection of Chicago Blue dye 
solution, as previously described 87.  With the blue dye method, implantation and 
interimplantation sites can be separately excised, and sections with the 
implanting embryo can be analyzed.  On day 8 of pregnancy, blue dye injection is 
not necessary, since implantation sites are visually distinguishable.  All mice in 
the present investigation were treated in accordance with the National Institutes 
of Health and institutional guidelines on the care and use of laboratory animals.     
 
MALDI-MS Data.   Implantation and interimplantation sites were dissected from 
the uterus, snap-frozen, sectioned (11 μm) in a cryostat and thaw-mounted onto 
MALDI MS compatible glass slides.   Tissues analyzed include pre-implantation 
uterine sections (Day 4 of pregnancy) and implantation site sections (Day 5, Day 
6, Day 7 and Day 8).   MALDI-TOF Images were acquired on an Ultraflex (Bruker 
Daltonics, Billerica, MA) Mass Spectrometer.  MALDI-FTICR Images were 
acquired on a 9.4 T Apex III (Bruker Daltonics, Billerica, MA) Mass Spectrometer.  
The lateral resolution of images depicted in Figures 9 and 10 was 100 μm 
(positive ion mode images) and 150 μm (negative ion mode images) for the 
MALDI-TOF data and 250 μm (positive mode images) and 150 μm (negative 
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mode images) for the MALDI-FTICR data.  For positive mode figures, the most 
intense [M+K]+ form of each phospholipid species is depicted, although each type 
of adduct  ([M+H]+, [M+Na]+ and [M+K]+) showed the same localization pattern.  
Matrix application in positive and negative mode utilized dry-coating methods 7 to 
deposit 2,5-dihydroxybenzoic acid (DHB) and ultra fine nebulization to deposit 
2,5-dihydroxyacetophenone (DHA) (9 mg DHA, 6 μl aniline, 700 μl ethanol, 300 
μl DI water) on tissue sections, respectively.   
 
MALDI-MS/MS Data.  The Day 8 images, located in the bottom of Figure 9 and 
10, were acquired on a 9.4 Tesla FTICR mass spectrometer with a mass 
accuracy of +/- 0.005 Da at m/z of 1,000 (5 ppm).  The LIPID metabolites and 
pathways strategy (LIPID MAPS) online resource was used to search for 
possible lipid structures that could match our experimental mass (+/- 0.005 Da).  
Although only one theoretical mass matched in each case, multiple fatty acid 
isobars with the same exact mass are possible.  Thus, MS/MS fragmentation of 
phospholipids was implemented to confidently determine the fatty acid chains.  
Fragmentation of PIs, PSs and PEs in negative ion mode generates fatty acid 
peaks and corresponding lysospecies 115.  Characteristic fragmentations of PCs 
in positive ion mode contain only one fragment corresponding to the head group  
(m/z 184 Da).  To obtain more fragment peaks for PCs, the matrix was doped 
with lithium chloride 67, 119.  Fragmentation peaks for each lipid in positive ion 
mode and negative ion mode are listed in Table 1 and 2, respectively.   Figure 
17 contains MS/MS spectra. 
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All MS/MS experiments were performed on a MALDI-Linear Ion Trap 
Quadrupole mass spectrometer (MALDI-LTQ, Thermo Electron Corporation, San 
Jose, CA).  For fragmentation of phospholipids, matrix was hand spotted; DHA 
was used for negative mode analysis and DHA with 100 mM LiCl was used for 
positive mode fragmentation.  In MS/MS imaging experiments, tissue sections 
were spotted at a lateral resolution of 230µm (Portrait 630 reagent Multi-Spotter, 
Labcyte, Sunnyvale, CA) 
 
LC-MS/MS Data.   All LC-MS/MS experiments were performed on a hybrid triple 
quadrupole/ linear ion trap mass spectrometer (4000 QTrap, Applied Biosystems, 
Foster City, CA).  Each experiment required approximately 15 mg of tissue.  LC-
MS quantitation of phospholipids followed previously published protocols 76.  
Specifically, we use 4 odd carbon internal standards per lipid class (25:0 [low 
mass] to 43:6 PUFA [high mass]).  We produce standard curves using multiple 
naturally occurring even carbon standard for each class (tied to the intensity of 
the internal standards).  Identification of individual phospholipids was achieved 
by LC-MS/MS fragmentation analysis.  Table 3 contains the results for some of 
the phospholipids analyzed (3 replicate experiments for the analysis of top and 
bottom hemispheres of day8 implantation sites [top1, top2, topM / bot1, bot2, 
botM]). 
 
Immunohistochemistry.  The COX-2 antibody was purchased from Cayman 
(Ann Arbor, MI) 98.  Localization of protein in formalin-fixed paraffin-embedded 
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uterine sections (5 µm) was achieved as previously described 120.  In brief, after 
deparaffinization and hydration, sections were subjected to antigen retrieval using 
a pressure cooker in 10 mmol/L sodium citrate solution (pH 6.0) for 20 minutes.  
A Histostain-Plus kit (Zymed, San Francisco, CA) was used to visualize the 
antigen; brown deposits indicate sites of positive immunostaining. 
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Table 1 
 
Assignment of lipid molecular species in MS/MS positive ion mode 
Class 
Molecular species 
 (C1 acyl chain/ C2 
acyl chain) Ion Type m/z ª Lithium induced MS/MS Peaks ^ 
SM 16:0 [M+H]+ 703.573 650 
  [M+Na]+ 725.555  
  [M+K]+ 741.529  
PC 32:0 (16:0/16:0) [M+H]+ 734.568 681, 551, 557, 484, 425, 478 
  [M+Na]+ 756.551  
  [M+K]+ 772.526  
PC 34:0 (16:0/18:0) [M+H]+ 762.6 709, 579, 585, 484, 425, 512, 506, 453 
  [M+Na]+ 784.581  
  [M+K]+ 800.554  
PC 34:1 (16:0/18:1) [M+H]+ 760.584 707, 583, 577, 510, 451, 478, 484, 425 
  [M+Na]+ 782.564  
  [M+K]+ 798.539  
PC 36:1 (18:0/18:1) [M+H]+ 788.614 735, 611, 605, 510, 451, 506 
  [M+Na]+ 810.594  
  [M+K]+ 826.569  
PC 34:2 (16:0/18:2) [M+H]+ 758.568 705, 581, 575, 508, 449, 478, 484, 425, 502 
  [M+Na]+ 780.548  
  [M+K]+ 796.524  
PC 36:2 (18:0/18:2) [M+H]+ 786.6 733, 609, 603, 508, 449, 506, 512, 453, 502 
  [M+Na]+ 808.581  
  [M+K]+ 824.554  
PC 36:4 (16:0/20:4) [M+H]+ hidden by 34:1 Na+ 729, 605, 599, 532, 473, 478, 425, 484 
  [M+Na]+ 804.55  
  [M+K]+ 820.524  
PC 38:4 (18:0/20:4) [M+H]+ no peak 633, 757, 627, 532, 473, 506, 526, 512, 453 
  [M+Na]+ 832.58  
  [M+K]+ 848.554  
PC 40:6 (18:0/22:6) [M+H]+ 834.596 781, 657, 651, 556, 497, 506, 453, 512 
  [M+Na]+ 856.581  
  [M+K]+ 872.554  
 
 
ª Data acquired on a MALDI-FTICR MS    
^ arrangement - highest intensity ion (left) to lowest intensity ion (right) in the MS/MS spectra (decimal values not 
included) 
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Table 2   
 
Assignment of lipid molecular species in MS/MS negative ion mode 
Class m/z ª  MS/MS Peaks ^ 
Molecular species  
 (C1 acyl chain/ C2 acyl chain) 
LPI 599.332 283, 419, 315 18:0 
PE 716.528 281, 255, 452, 478 34:1 (16:0/18:1) 
PG 747.521 281, 255, 391, 465, 483, 491, 509 34:1 (16:0/18:1) 
PS 788.551 701, 419, 283, 417, 504 36:1 (18:0/18:1) 
PI 857.522 553, 391, 571, 303, 255, 439, 601, 297 36:4 (16:0/20:4) 
PI 885.553 581, 419, 283, 599, 601, 303, 439, 297, 619 38:4 (18:0/20:4) 
PE 764.529 303, 281, 478 38:5 (18:1/20:4) 
PI 883.541 579, 417, 281, 597, 601, 303, 297, 439, 619 38:5 (18:1/20:4) 
PEp 750.549 331, 436 38:4 (16:0p/22:4) 
PI 837.556 581, 419, 283, 553, 599, 391, 297 34:0 (18:0/16:0) 
PI 833.523 553, 391, 577, 255, 571, 279, 297 34:2 (16:0/18:2) 
PI 861.558 581, 419, 283, 577, 599, 415, 279, 297 36:2 (18:0/18:2) 
PS 786.534 699, 419, 283, 415,279 36:2 (18:0/18:2) 
PEp 746.517 327, 436, 418 38:6 (16:0p/22:6) 
PI 909.556 581, 419, 283, 599, 625, 297, 327 40:6 (18:0/22:6) 
PE 742.543 279, 283, 281, 480, 478 36:2 (18:0/18:2, 18:1/18:1)* 
PE 770.575 279, 283, 281, 460, 508, 307 38:2 (20:0/18:2, 18:0/20:2, 18:1/20:1)* 
    
 
 
ª Data acquired on a MALDI-FTICR Mass Spectrometer  
^ arrangement - highest intensity ion (left) to lowest intensity ion (right) in the MS/MS spectra (decimal values not 
included) 
* acyl chain identities confirmed by MS/MS imaging  
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Supplementary Table 3.  LC-MS/MS Data 
Predominantly bottom expression (AM pole) 
weights (mg tissue): 15 15 15 14.5 15 15 
values below are ng lipid/mg tissue top1 top2 topM bot1 bot2 BotM 
GPA(36:2) 6 5.6 5.2 8.2 10.8 6.1 
GPA(38:4) 4.6 4.3 4.2 6.1 6.7 5.7 
GPA(40:6) 12.9 13.4 11.2 19.7 18.9 13.9 
GPCho(32:1e)/GPCho(32:0p) 1.1 0.6 1.1 1.9 1.7 1.3 
GPCho(34:2)* 44.4 41.1 43.6 55.2 55.4 50.9 
GPCho(36:4)* 71.9 69.0 73.7 97.1 67.2 83.6 
GPCho(36:4p) 3.5 2 4.2 5.1 5.1 5.4 
GPCho(38:4) 166.1 157.7 152.3 160.1 177.5 168.7 
GPCho(38:6e)/GPCho(38:5p) 5 4.4 5.1 6.8 13.1 7 
GPCho(40:6)* 77.2 67.8 79.9 80.1 133.9 83.9 
GPEtn(34:2) 6.4 6.5 5.5 7.2 6.4 8 
GPEtn(36:0) 41.3 30.2 40.9 52.2 62.7 43.3 
GPEtn(36:4e)/GPEtn(36:3p) 4.4 2.8 4 5.3 4.7 4.6 
GPEtn(38:4) 81.2 76.5 71.3 97 80.8 94.4 
GPGro(36:3) 16.7 14.1 15.3 21.1 30.5 17.5 
GPGro(36:4) 10.6 8.6 8.8 18.1 26.7 14.5 
GPGro(38:1) 1.4 1 1.3 1.8 2.5 1.5 
GPGro(42:10) 4.9 4 5 8.1 14.4 7 
GPGro(44:10) 4.2 3.3 3.8 4.8 6.4 4.3 
GPGro(44:11) 6.5 5.2 6.5 10.1 10.5 8.2 
GPGro(44:12) 21.3 16.4 21.1 31 39.5 27.2 
GPIns(32:0) 0.3 0.5 0.4 1 1.2 1.1 
GPIns(34:1) 3.9 3.6 3.4 6.2 9 6.5 
GPIns(34:2)* 4.3 3.9 4.5 11.4 17.6 9.9 
GPIns(36:1) 1.6 1.7 1.9 4.1 5.4 3.8 
GPIns(36:2) 6.2 6 6.6 16 22.1 13.2 
GPIns(38:6) 1.7 1.5 1.3 2.9 3 2.4 
GPIns(40:4) 1.8 1.7 1.9 2.6 2 2.3 
GPIns(40:6)* 2.4 2.3 2.5 4.7 5.4 4 
GPSer(38:4) 49.8 48.4 44.2 66.4 61.1 50.6 
GPSer(42:8) 0.8 0.4 0 0.9 1.2 0.8 
GPThr(38:4) 2.4 2.7 2.5 3.8 3.2 3 
 
*LC-MS/MS data correlates with MALDI images 
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Supplementary Table 3.  LC-MS/MS Data 
Predominantly top expression (M pole) 
weights (mg tissue): 15 15 15 14.5 15 15 
values below are ng lipid/mg tissue top1 top2 topM bot1 bot2 BotM 
GPA(32:1) 0.9 0.7 0.8 0.6 0 0 
GPA(34:1) 4.6 4 4 3.4 3.8 2.6 
GPCho(30:0) 10.9 10.7 10.2 8.9 6.9 7.3 
GPCho(32:1) 30.8 29.7 29.5 23.7 20.4 20.3 
GPCho(34:0) 19.4 17 19.5 14.4 12.5 14.4 
GPCho(34:0e) 2.5 2 2.2 1.5 1.8 1.4 
GPCho(34:1)* 57 55.7 56.5 46 33.3 42.1 
GPCho(34:1e)/GPCho(34:0p) 11.3 12.1 10.2 9 9.2 7.1 
GPCho(36:1) 74.1 73.3 73.2 54.2 60.8 55.2 
GPCho(36:1e)/GPCho(36:0p) 1.4 1.2 1.1 0.7 0.8 0.7 
GPCho(36:3) 49.2 48.7 49 40.9 39 41.6 
GPCho(38:2) 8 8.3 7.5 3.3 4.4 3.4 
GPCho(38:5) 48.7 45.8 45.3 39.9 33.8 38.8 
GPCho(40:1) 29.8 24.3 29.1 25.8 22.9 22.5 
GPCho(40:7) 20.5 15.6 17.4 12 10.4 12.6 
GPEtn(32:0) 1.2 1.1 0.8 0.6 0 0.5 
GPEtn(32:1) 0.8 0.7 0.9 0.4 0.3 0.5 
GPEtn(34:0) 2.6 2.1 2.5 1.8 1.3 1.5 
GPEtn(34:1)* 13.3 13.5 13.1 10.4 8.1 10.5 
GPEtn(38:3e)/GPEtn(38:2p) 6.4 9.5 4.1 5.2 3.5 4 
GPEtn(40:4e)/GPEtn(40:3p) 12.3 15.1 9.2 9.5 0 8.3 
GPEtn(40:7) 19.5 18.3 18.4 18 16.3 16.4 
GPEtn(42:10) 2.9 4 1.7 1.4 1.2 1.2 
GPEtn(42:5) 1.8 1.9 1.6 1.4 1 1.3 
GPGro(38:2) 0.9 0.8 0.7 0.5 0.6 0.5 
GPIns(38:5)* 8.7 9.7 8.5 8.2 6.1 7.2 
GPSer(34:1) 19.5 21.3 17.5 13.4 14.1 11.1 
GPSer(38:1) 3.6 2.9 2.4 2.3 1.9 1.9 
GPSer(40:2) 3 2.9 2.3 1.4 0.9 1.2 
GPSer(40:3) 3.1 3.2 2.1 2.3 2.1 1.5 
GPSer(42:3) 2.2 2.2 1.9 2 1.4 1.4 
 
*LC-MS/MS data correlates with MALDI images 
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CHAPTER IV.   
 
DETECTING SPATIAL AND TEMPORAL DISTRIBUTIONS OF 
PROTEINS DURING EMBRYO IMPLANTATION BY MALDI IMAGING 
MASS SPECTROMETRY 
 
A.  Overview 
Imaging mass spectrometry analysis of uterine sections provided 
molecular composition, relative abundance and spatial distribution of a large 
number of proteins during the embryo implantation period.  This approach has 
allowed us for the first time to choreograph in situ proteome profiles of mouse 
implantation and interimplantation sites in a region and stage specific manner 
with the progression of implantation.  This application is reliable since patterns of 
expression of several proteins displayed by imaging mass spectrometry correlate 
well with in situ hybridization and immunohistochemistry results.  Interestingly, 
the use of this approach has provided new insights regarding uterine biology of 
cPLA2α null females that show implantation defects.   
 
B.  Introduction 
The heterogeneous cell types of the uterus, each with unique functions, 
pose a challenge for studying events during early pregnancy.  This complexity is 
increased because their actions change, depending on their proximity to the 
implanting embryo and with pregnancy progression.  Therefore, studying the 
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uterine molecular landscape using conventional approaches presents a laborious 
task.   
 Although expression studies by in situ hybridization and 
immunohistochemistry have provided profiles of specific genes and their gene 
products during implantation and decidualization 1, 2, the in situ spatiotemporal 
distribution of a large number of gene products in uteri during implantation 
remains poorly understood.  Here we used in situ imaging mass spectrometry to 
generate proteomic profiles in the periimplantation mouse uterus.  Whereas 
mass spectrometry is an effective technology for identifying proteins and their 
post-translational modifications under various physiological conditions 15, 49, 
imaging mass spectrometry is a powerful tool for in situ analysis of proteome 
profiles on tissue sections 121, 111.  This technology allowed us for the first time to 
analyze hundreds of proteins involved in proliferation, differentiation and 
apoptosis during the periimplantation period, providing unique and differential 
proteomic blueprints of implantation and interimplantation sites.  The uterine 
proteomic profile in mice lacking Pla2g4a, the gene encoding for cytosolic 
phospholipase A2α (cPLA2α), was also compared with wild-type implantation 
sites, providing new insight regarding uterine biology in these null females that 
display implantation defects.   
 
C.  Results 
C.i.  Protein signatures differ within specific regions of implantation and 
interimplantation sites.  Implantation in mice occurs at the anti-mesometrial 
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pole of the uterus.  On the afternoon of day 5 of pregnancy, the proliferating 
stromal cells surrounding the implanting embryo begin to differentiate into 
decidual cells, forming the avascular primary decidual zone (PDZ).  By day 6, the 
PDZ is well differentiated and formed, and a secondary decidual zone (SDZ) 
forms around the PDZ, coinciding with the cessation of proliferation in the PDZ 
with continuing proliferation in the SDZ.  The SDZ is surrounded by circular and 
longitudinal muscle layers, collectively referred to as the myometrium.  In Figure 
21a, the anti-mesometrial pole (AM), mesometrial pole (M), PDZ and SDZ are 
demarcated by faux matrix spots on a representative section from a day 6 
implantation site (IS).  This figure also depicts an interimplantation site (Inter-IS) 
which contains all the major cellular regions except the PDZ and SDZ, since they 
are formed in response to the implanting blastocyst (Figure 21a).   
To characterize the proteome signatures between specific regions within 
the implantation and interimplantation sites, frozen sections from these sites on 
day 6 of pregnancy were thaw-mounted onto glass slides and subjected to 
profiling mass spectrometry analysis.  Briefly, matrix spots (230µm in diameter) 
were deposited on particular areas of interest (Figure 21a).  Profiling mass 
spectrometry generated spectra from those matrix spots, where each mass-to-
charge (m/z) value corresponds to a unique protein which is subsequently 
identified.  In this analysis, approximately 230 distinct peaks were found within 
the optimal mass range, which for MALDI-time-of-flight-mass spectrometry (MS) 
is 2–30 kilodalton (kDa).  This is dictated by instrumental parameters.  The 
instrument is operated under delayed extraction conditions; thus, enhanced 
70 
 
sensitivity, resolution and mass accuracy are observed for ions less than 50,000 
Da.  Microchannel plate detection is velocity dependent; thus, higher molecular 
mass ions (having lower velocities) have lower probabilities of being detected 
unless they are highly abundant.  Clusters of matrix molecules below 2,000 Da 
complicate the mass spectra and potentially mask expression of low-molecular-
mass peptides.   
Statistical analyses of spectra from IS and inter-IS revealed 50 peaks as 
significantly changed due to the presence and proximity of the embryo.  The 
average mass spectra from specific uterine regions for ubiquitin (m/z 8565), 
calgizzarin (m/z 10952), calcyclin (m/z 9962) and transthyretin (m/z 13641) are 
shown in Figure 21b.  These four proteins were selected and chosen for further 
analysis because of their unique expression patterns in the uterus and their 
reported involvement during pregnancy 122-124.  In addition, these proteins are 
known to participate in protein degradation, cell differentiation, cell proliferation 
and retinol binding, respectively.  Statistical analysis shows that ubiquitin is up-
regulated at IS by 3.4-fold, compared with inter-IS on d 6 of pregnancy.  In 
contrast, calcyclin and calgizzarin are up-regulated by 5.2- and 2-fold, 
respectively, in the PDZ, compared with the SDZ, whereas transthyretin is up-
regulated in the SDZ near the antimesometrial pole (5.1-fold higher in the SDZ, 
compared with the PDZ, and 2.9-fold higher in antimesometrial pole, compared 
with the mesometrial pole).  Unique spatial locations of these proteins, as 
determined by imaging mass spectrometry, are described below. 
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 To view these spatiotemporal differences in expression, implantation and 
interimplantation sites were sectioned on days 5, 6, and 8 of pregnancy and 
prepared for imaging mass spectrometry.  Using this technique, a raster of the 
entire tissue section produces an ordered array of mass spectra that generates 
2D images showing localization of each m/z value in the X and Y direction.  Our 
analysis shows that ubiquitin is expressed at higher levels at implantation sites 
on days 6 and 8 of pregnancy compared with interimplantation sites (Figure 22a, 
upper).  Calcyclin is expressed at higher levels immediately adjacent to the 
implanting embryo with expression concentrated at the antimesometrial pole on 
day 8 (Figure 22b, upper).  While the expression of calgizzarin is also primarily 
localized at the antimesometrial pole on both days 6 and 8 of pregnancy (Figure 
22c, upper), transthyretin expression is prominent along the outer edge of the 
stroma underlying the myometrium (Figure 22d, upper).   
 
C.ii.a.  Correlating protein images with mRNA localization using in situ 
hybridization.  To determine whether proteins identified by imaging analysis 
correlates with their mRNA localization, in situ hybridization of ubiquitin, calcyclin, 
calgizzarin and transthyretin with 35S-labeled probes was performed on frozen 
uterine sections from the corresponding days of pregnancy.  We found a high 
correlation between protein and mRNA localizations with the exception of 
transthyretin whose transcripts were detected at low levels in the uterus with an 
interesting pattern in the day 6 and day 8 embryos (Figure 22a, b, c, and d, 
lower).  It can be speculated that imaging did not detect transthyretin in day 6 
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and 8 embryos because it could be detected at a different mass in these regions 
due to posttranslational modifications.  In addition, imaging mass spectrometry 
showed distinct expression patterns of a large number of proteins on days 4, 5, 
6, and 8 of pregnancy (Figure 23 and Table 4).  Differential region-specific 
distribution of these proteins on day 6 of pregnancy with their potential biological 
functions is depicted in Figure 23 and Table 4.  It is interesting to note that the 
SDZ shows relative increases in proteins involved in energy production and 
proliferation, characteristic processes occurring in this zone.  Conversely, the 
PDZ shows increases in proteins influencing hormone signaling.   
 
C.ii.b.  Immunohistochemistry and activity assays confirm protein 
identification and spatial distribution.  Immunohistochemistry (IHC) was 
performed in sections of day 6 (D6) implantation sites for Purkinje Cell Protein 4 
(PEP-19).  Both IHC and IMS showed PEP-19 localization to predominantly be in 
the muscle layer (myometrium) surrounding the uterus (Figure 24a).  IHC was 
also performed in sections of day 8 (D8) implantation sites for calcyclin, 
calgizzarin and transthyretin to see whether mass spectra correlate with 
immunolocalization.  The results show that localization patterns of these four 
proteins are in agreement with mass spectra, although immunohistochemistry 
also detected expression of transthyretin in the embryo (Figure 24a).  In Figure 
24b, the enzymatic activity of cytochrome c oxidase (COx), a multi-subunit 
complex within the mitochondrial respiratory chain, was compared to the IMS 
results of one of the COx subunits, VIb, on day 5 (D5), D6, and D8.  Both 
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experiments showed increased expression in the lumen and embryo on D5, in 
the uterine stroma around the embryo on D6, and in the uterine stroma in the 
bottom (AM) pole on D8 (Figure 24b).   
 
C.ii.c.  Isotope Coded Affinity Tag based protein profiling confirms profiling 
and imaging mass spectrometry experimental results.  Isotope Coded Affinity 
Tag (ICAT) labeling methods and LC-MS/MS analyses were used to quantify and 
identify proteins in implantation and interimplantation sites on day 6 of pregnancy 
(Figure 25).  ICAT results showed a relative expression increase in the 
implantation sites for thioredoxin 1 and 40S ribosomal protein S28 and S21 by 
28%, 35% and 22%, respectively; whereas, macrophage migration inhibitory 
factor showed a 25% increase in interimplantation sites (Figure 25, left).  
Consequently, the ICAT data matched the profiling and imaging mass 
spectrometry data (Figure 25, middle and right).  Although, relative protein 
expression changes were much less in our ICAT study compared to profiling and 
imaging experiments we were able to conclude even small changes (>10%) were 
statistically significant (see Materials and Methods for details).  One of the 
limiting factors for the ICAT study was the availability of adequate amounts of 
tissues, since 100 mg of protein was needed from each sample type.  Entire IS 
and Inter-IS were homogenized, yet most molecules only localize to particular 
cell types, explaining why ICAT only detected small changes in protein 
expression.   
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C.iii.  Exploring protein expression along the Z-axis of a day 6 implantation 
site.  Imaging mass spectrometry was also used to analyze serial sections of a 
day 6 implantation site to explore the relative protein expression in the Z direction 
(Figure 26a).  As shown in Figure 26b, ubiquitin, calcyclin, and calgizzarin all 
show varying expression patterns in the uterine stroma depending on their 
proximity to the implanting embryo, whereas expression of purkinje cell protein 4 
remains relatively unchanged in the myometrium. 
 
C.iv.  Characterizing differential proteome profiles in the Pla2g4a null mice.  
The success of our application of IMS in wild-type periimplantation uteri 
prompted us to utilize this approach in Pla2g4a null females with known defects 
in implantation.  Pla2g4a encodes cytosolic phospholipase A2α (cPLA2α) which 
liberates arachidonic acid from membrane phospholipids for prostaglandin 
biosynthesis by the cyclooxygenase system 125-127.  Our previous study 
suggested that compromised pregnancy outcome in Pla2g4a null females results 
from deferral of on-time implantation, leading to subsequent retarded 
fetoplacental development and reduced litter sizes 95.  This study advanced a 
new concept that a short delay in the initial attachment reaction propagates 
detrimental ripple effects later in pregnancy.  This is now supported by a more 
recent study using Lpa3 null mice 95, 104.  This deferred implantation phenomenon 
in Pla2g4a null females results in both “on-time” and “deferred” implantation 
sites, morphologically distinguishable by their differing sizes on day 6 of 
pregnancy (Figure 27, left).   
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We used profiling and imaging mass spectrometry to address whether 
proteome signatures on day 6 of pregnancy differ between on-time implantation 
sites in wild-type and Pla2g4a null mice and between on-time and deferred 
implantation sites in Pla2g4a null females.  We speculated that while proteome 
profiles of “on-time” implantation sites in Pla2g4a null females would be similar to 
those of wild-type females, deferred implantation sites in Pla2g4a null females 
would be more similar to day 5 implantation sites in wild-type females.  
Surprisingly, we found that while expression/localization of some proteins did 
show remarkable changes, these differences were mostly attributed to the lack of 
Pla2g4a rather than to differences in implantation timing (Figure 27, middle and 
Figure 28).   
 The four proteins that were characterized in wild-type day 6 uteri were 
selected for further analysis in Pla2g4a null uteri.  While the expression of 
ubiquitin did not differ dramatically between WT and Pla2g4a null uteri, 
calgizzarin, calcyclin, and transthyretin showed pronounced differences.  
Specifically, calgizzarin expression was found to be reduced in Pla2g4a null uteri, 
but more interestingly, its localization shifted to the luminal epithelium in null uteri 
as opposed to its predominant expression in the antimesometrial decidua of wild-
type uteri (Figure 27, middle and right).  Calcyclin expression was evident in 
the PDZ of wild-type uteri, and in the implanting embryo in Pla2g4a null females, 
with lowest expression in deferred implantation sites in Pla2g4a null females 
(Figure 27, middle and right).  In contrast, the expression of transthyretin was 
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higher in deferred implantation sites compared with on-time implantation sites in 
Pla2g4a or wild-type females (Figure 27, middle and right).   
 Previous characterization of Pla2g4a null mice inferred that while a short 
deferral of on-time implantation leads to subsequent developmental defects, 
those that implanted on-time developed normally during the subsequent course 
of pregnancy.  However, our proteomics results suggest that proteome 
signatures differ between wild-type and Pla2g4a null uteri regardless of the 
timing of implantation.  These are exciting results that will provide deeper 
understanding of the implantation process. 
 
D.  Discussion 
In situ localization and identification of a broad proteomic landscape in a 
given region of tissues remains difficult with current labeling procedures.  
Therefore, direct analysis of tissue sections by matrix-assisted laser 
desorption/ionization (MALDI) mass spectrometry holds great potential.  Both 
direct tissue profiling and imaging provide region-specific detailed assessment of 
the complex protein patterns within a tissue.  These techniques also have the 
advantage of interrogating tissues for protein identification and localization 
without the limitation of selecting specific proteins for analysis.  The present data 
provide novel proteomic approaches to identify protein signatures within and 
between implantation sites during the periimplantation period.   
In this study, four proteins of interest were selected for more detailed 
analysis because of their unique uterine expression patterns.  Interestingly, these 
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proteins have previously been implicated to play roles during pregnancy.  For 
example, calcyclin is known to be expressed at high levels in day 8 and day 9 
decidua 124 and it influences placental lactogen secretion in mice 122.  Although 
our imaging mass spectrometry results show similar expression pattern of 
calcyclin protein on day 8 of pregnancy, its differential expression pattern in 
periimplantation uteri suggests that calcyclin is also important for early pregnancy 
events.  In contrast, roles for calgizzarin in early pregnancy remain largely 
unexplored.  However, one study identified this protein as a downstream target of 
neurokinin B (NKB), which is secreted at high levels from the placenta during 
preeclampsia, and is known to suppress calgizzarin expression 128.  These 
results suggest that calgizzarin has beneficial roles in pregnancy maintenance.  
This contention is supported by our present findings of reduced calgizzarin 
expression in Pla2g4a null females which display implantation, decidualization 
and placental defects 95.   
Transthyretin, a protein involved in transporting both thyroxin and retinol-
binding protein, is aberrantly expressed in placental tissues of patients with 
pregnancy loss, suggesting its important role in placentation 129, 130.  Indeed, Ttr 
mRNA is detected in human placentas with protein expression specifically in the 
syncytiotrophoblast 123.  While our studies focused on implantation and early 
pregnancy events, it will be of great interest to use this proteomic approach to 
determine differential proteome profiles during later events of pregnancy 
including placentation.   
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Our success in employing imaging mass spectrometry to study uterine 
biology in wild-type mice during normal pregnancy provoked us to employ this 
approach to mice with known defects in implantation.  We used Pla2g4a null 
mice to investigate whether the proteomic landscape differed between wild-type 
and null uteri.  Pla2g4a null females show deferral of on-time implantation, 
leading to subsequent adverse ripple effects throughout the course of pregnancy 
and ultimately reduced litter size 95.  We hypothesized that those embryos that 
implant beyond the normal window of implantation undergo premature demise 
and those that implant on-time develop normally.  However, our proteomics 
results suggest that proteome signatures differ between wild-type and Pla2g4a 
null uteri regardless of implantation timing.  This finding is interesting and may 
help distinguish which proteins are critical for on-time implantation.  In this 
respect, the power of IMS in generating proteome signatures within and between 
implantation sites is remarkable.   
Dysregulation of events before, during, or immediately after implantation 
contributes to poor pregnancy outcome 2.  Therefore, understanding the interplay 
of numerous proteins during implantation is essential to identify potential targets 
for treating infertility and developing novel contraceptives approaches.  This 
study examining differential protein signatures between and within implantation 
sites and interimplantation sites on different days of pregnancy has opened up a 
new avenue of exploring protein profiles and their interactions during normal and 
defective implantation.  
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E.  Materials and Methods 
Mice.  Adult CD-1 mice were purchased from Charles River Laboratory (Raleigh, 
NC).  Females were mated with fertile males of the same strain to induce 
pregnancy.  Mice were sacrificed between 0900 and 1000 h on the specified day 
of pregnancy (day 1 = vaginal plug).  The disruption of the Pla2g4a gene was 
originally achieved in J1 ES cells by homologous recombination as described 125.  
Genotyping was by PCR analysis of genomic DNA.  Implantation sites on days 5 
and 6 of pregnancy were visualized by an intravenous injection of Chicago Blue 
dye solution, as previously described by us 87.  All mice in the present 
investigation were housed and used in accordance with the National Institutes of 
Health and institutional guidelines on the care and use of laboratory animals. 
 
Protein profiling and imaging experiments.  Implantation sites (IS) and 
interimplantation sites (Inter-IS) were dissected from the uterus, snap-frozen, 
sectioned (11 μm) in a cryostat, thaw-mounted onto matrix-assisted laser 
desorption/ionization (MALDI) mass spectrometry compatible glass slides and 
rinsed in a series of reagent grade ethanol/water washes (70% for 30 seconds 
(s), 70% for 30 s, and 100% for 15 s).  A thin layer of fine sinapinic acid (SA) 
crystals was applied to vacuum dried tissue sections (seeding).  Mechanical 
grinding with a mortar and pestle results in 1-40 μm sized crystals.  An Acoustic 
Reagent Multispotter (Labcyte Inc, Sunnyvale, CA)  was used to deposit SA 
matrix spots (25 mg/ml in 50% Acetonitrile (AcN), 0.1% Trifluoroacetic acid 
(TFA)) over distinct regions of IS and Inter-IS 131.  Different matrix deposition 
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techniques were used for the profiling experiment (13 drops [stop/start mode] 3 
passes) and the imaging experiment (1 drop [start/stop mode] 5 passes).  All 
experiments were performed in the linear mode geometry on an Autoflex MALDI-
TOF-MS (Bruker Daltonics, Billerica, MA) equipped with a solid-state Smartbeam 
laser operating at 100 Hz.  The experimental design is illustrated in Figure 29.   
In the profiling study, matrix spots (230μm in diameter) were deposited 
over unique cell types within the IS and Inter-IS.  In the imaging study, uterine 
sections were uniformly spotted with SA matrix solution (120μm in diameter, 
150μm center to center spacing defining the resolution).  A partial 3D study 
explored the influence of the embryo along the Z axis on day 6 of pregnancy.  A 
section of mouse uterus containing an IS flanked on one side by Inter-IS was 
analyzed.  Every fifth section (55µm apart) was collected until the embryo was 
reached and then every section was collected.  After analysis, the distance of 
each uterine section from the center of the IS (location of embryo) was 
calculated.  All images directly compared were run on the same day and on the 
same MALDI glass plate.   
 
Spectra preprocessing.  For all studies, Pro TS-Data (Biodesix Inc.  Steamboat 
Springs, CO) was used for spectra processing.  Spectra from profiling and 
imaging experiments were baseline subtracted and normalized to the total ion 
current (sum of all intensities in the entire spectrum [TIC]) 35.  To ensure this 
spectral processing does not alter the spatial localization of protein images we 
compared the normalized and un-normalized images for each protein of interest 
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(Figure 30).  Normalization adjusts for pixel to pixel variations but the overall 
spatial localization is not altered in Figure 30.  Normalizing the data makes it 
possible to compare data acquired on different days as demonstrated by Figure 
31.  The study in Figure 31 analyzed a mouse implantation site from day 6 of 
pregnancy.  Sections were collected through the center of the implantation site, 
washed and matrix was applied using a robotic spotter as described above.  
Mass spectra acquisition was carried out on one section at a time every third day 
for 2 weeks.  MS preprocessing consisted of noise removal, baseline subtraction 
and TIC normalization.  Three proteins were visualized on each section; PEP-19 
(green), 40S ribosomal protein S28 (red), and homeodomain-only protein (blue).  
Each of these proteins localized to a different tissue type: PEP-19 to the muscle 
surrounding the uterus, 40S ribosomal protein S28 to the uterine stroma, and 
homeodomain-only protein to the embryo.  Most importantly, both spatial 
localization and peak intensity information were retained throughout the two 
week period of MS acquisition.  The results reflect the general stability of spotted 
tissue sections over time, stored in a vacuum dessicator; thereby, supporting 
previously published results 132. 
 
Statistical Analysis.  In profiling studies of different cell types in wild-type mice, 
three sections were taken from each mouse (n=5) at either the implantation site 
or interimplantation site.  For each section, 1 to 3 spectra were acquired within 
each different cellular region.  In the profiling study of Pla2g4a null mice, 7 to 10 
sections were taken from each Pla2g4a null mouse with either on-time 
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implantation or deferred implantation, and from each wild-type mouse with on-
time implantation.  About 7 spectra were acquired for each section.  Following 
processing, multiple spectra from each individual animal were averaged over 
each cellular region of implantation and interimplantation sites.  Features were 
extracted from the average spectrum.  For imaging, Biomap (Novartis, Basel, 
Switzerland) was used for plotting 2D ion density maps (x and y dimension) of 
selected mass-to-charge (m/z) values (wild-type [n ≥ 3 for each day of pregnancy 
analyzed] and Pla2g4a [n ≥ 3 for differed and on-time ISs and Inter-ISs]).   
 Statistical analysis of wild-type [n=30] and Pla2g4a null [n=30] profiles 
revealed peaks of significance.  Significance Analysis of Microarrays (SAM) for 
paired data was used to identify significant features between different cell types 
133.  SAM computes a statistic for each feature which is a measurement of 
difference in group means standardized by pooled within-group standard 
deviation.  SAM then uses a permutation method to evaluate the significance of 
the statistics of each feature.  False discovery rate (FDR) was used to control for 
the multiple testing.  An FDR less than 0.0001 was used as the cutoff for 
concluding a set of features significant.   
 
Protein identification experiments.  Excised day 6 and day 8 ISs were 
homogenized in Tissue Protein Extraction Reagent (TPER; Pierce, Rockford, IL) 
supplemented with protease inhibitors.  For each extract, a Vydac C8 polymeric 
reversed-phase column (3.2 x 150mm) fractionated 300 µg of protein solution (96 
min linear gradient from 2-90% Acetonitrile in 0.1% TFA) into a 96-well PCR 
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plate.  During separation, a liquid handling robot moves the transfer capillary 
sequentially into each of the 96 wells at 1 min intervals.  To identify wells 
containing proteins of interest in an automated process, 0.2 μL was removed 
from each well, mixed with SA matrix, and analyzed by MALDI-MS (Bruker 
Autoflex).  Fractions containing m/z values of interest were run on a gel (10-20% 
tricine) and bands of interest were excised and digested with trypsin gold 
(Promega; Madison, WI).  In solution trypsin digest was also performed on 
fractions which contained m/z values of interest.  Either an LTQ or LCQ (Thermo 
Scientific; Waltham, MA) was used to analyze digested proteins.  The peptides 
were separated on a packed capillary column, 75 μm x 10.5 cm, with C18 resin 
(Monitor C18, 5 μm; Column Engineering, Ontario, CA), using a linear gradient 
(5% to 95% Acetonitrile in 0.1% formic acid in water) delivered at 250 nL/min.  
MS/MS spectra were initially analyzed by searching the mouse International 
Protein Index database using Sequest software 134.  ProteinProphet software was 
then used to determine the probability that a protein had been correctly identified, 
based on the available peptide sequence evidence (Figure 32) 135, 136. 
 
In situ hybridization.  The cDNA clones for Calgizzarin, Calcyclin, Transthyretin, 
and Ubiquitin were generated by RT-PCR using the following specific primers: 
Calgizzarin (191 bp), 5’-GCA TTG AGT CCC TGA TTG CT-3’ and 5’-ATC TAG 
CTG CCC GTC ACA GT-3’; Calcyclin (165 bp), 5’-CAA GGA AGG TGA CAA 
GCA CA-3’ and 5’-AAG GCG ACA TAC TCC TGG AA-3’; Transthyretin (358 bp), 
5’-GCT TCC CTT CGA CTC TTC CT-3’ and 5’-CAG AGT CGT TGG CTG TCA 
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AA-3’; Ubiquitin (235 bp), 5’-GGT AAG ACC ATC ACC CTG GA-3’ and 5’-TCT 
TGC CTG TCA GGG TCT TC-3’.  For in situ hybridization, sense or antisense 
35S-labeled probes were generated by using appropriate polymerases from 
cDNAs as previously described by the Dey lab 88.  Sections hybridized with 
sense probes showed no signal and served as negative controls.  Probes had 
specific activities of approximately 2 x 109 dpm/µg. 
 
Immunohistochemistry.  Antibodies used included PEP-19 (provided by Dr.  
Malin Andersson, Stockholm, Sweden), Ubiquitin (Calbiochem, San Diego, CA), 
Calgizzarin (Proteintech Group, Chicago, IL), Calcyclin (Santa Cruz 
Biotechnology, Santa Cruz, CA) and Transthyretin (Santa Cruz Biotechnology).  
Localization of protein in formalin-fixed paraffin-embedded uterine sections (5 
µm) was achieved as previously described 120.  In brief, after deparaffinization 
and hydration, sections were subjected to antigen retrieval using a pressure 
cooker in 10 mmol/L sodium citrate solution (pH 6.0) for 20 minutes.  A 
Histostain-Plus kit (Zymed, San Francisco, CA) was used to visualize the antigen; 
brown deposits indicate sites of positive immunostaining. 
 
In Situ Cytochrome c oxidase activity staining in implantation sites.  COx 
activity tissue staining was performed according to previously published protocols 
137.  In brief, cytochrome c oxidase (COx) enzyme complex activity was 
visualized by immersing tissue sections in COx activity buffer (PBS [pH 7.4] 
containing 0.05% Di-amino benzidinetetrachloride [DAB], 0.02% reduced 
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cytochrome c, and 4% sucrose).  COx oxidizes cytochrome c, which then 
oxidizes DAB to form a red-colored precipitate.  After incubation, sections were 
washed with water, dehydrated with increasing concentrations of ethanol (50%, 
70%, 95%, 100%, and 100%) and xylene. 
 
Isotope Coded Affinity Tag (ICAT) based protein profiling.  The ICAT 
analysis of Implantation sites (IS) and control interimplantation sites (Inter-IS) 
from day 6 of pregnancy was carried out using the commercially available 
cleavable ICAT Reagent Kit (Applied Biosystems, San Francisco, CA, USA) 
according to the instructions provided by manufacturer.  Briefly, excised day 6 IS 
and Inter-IS were homogenized in Tissue Protein Extraction Reagent (TPER; 
Pierce, Rockford, IL) supplemented with protease inhibitors.  Equal protein 
concentrations (100 µg) were used for the ICAT analysis.  After reduction and 
denaturation, the IS and Inter-IS samples were labeled with biotin-conjugated 12C 
(light) and 13C (heavy) reagents at 37°C for 2 hr, respectively.  The two ICAT-
labeled samples were combined and digested with trypsin at a ratio of 1:10 with 
respect to the sample protein concentration at 37°C for 12 to 16 hr.  The digest 
was acidified and loaded into a cation exchange column equilibrated with 10 mM 
KH2PO4/25% acetonitrile, pH 2.5-3.3.  After neutralization, the biotinylated-ICAT-
labeled peptides were purified by avidin affinity cartridge prepared as per the 
manufacturer's instructions.  ICAT-labeled peptides were eluted with 30% 
acetonitrile, 0.4% trifluoroacetic acid in water.  The eluted peptides were 
evaporated to dryness and reconstituted in 100 μl of cleavage reagent for 2h at 
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37ºC to cleave the biotin portion of the tag from the labeled peptides.  The 
cleaved peptides were evaporated to dryness and re-suspended in aqueous 
solvent (100 μl H2O/0.1% formic acid).  Separations were carried out on an on-
line capillary LC system in reverse phase mode prior to MS/MS analysis using a 
LTQ (Thermo Scientific; Waltham, MA).  Gas-phase fractionation methods were 
used to increase proteome coverage; therefore, the mixture was analyzed six 
separate times, with the mass spectrometer selecting ions for fragmentation from 
a subset of the entire mass range for each run (m/z ranges: 400-500, 500-600, 
600-700, 700-800, 800-1000, 1000-2000) 138.  Protein ID’s were carried out using 
SEQUEST/ProteinProphet, and quantified in XPRESS.   
 ICAT analysis of IS and Inter-IS identified over 200 proteins (criteria > 1 
peptide/ protein; Trans-Proteomic Pipeline score of 1.0).  β-actin and β-tubulin 
are known to be equally abundant in IS and Inter-IS (relative ratios should be 
equal to one).  This data was useful in determining an approximate acceptable 
cutoff for fold changes in abundances for proteins of interest.  The three β-actin 
peptides analyzed had an average error of 7% from 1 (see table below).  The 
four β-tubulin peptides had an average error of 7.5% from 1.  Due to the small 
standard deviation even small changes in protein abundance between 
implantation sites and interimplantation sites are probably significant. 
 
Actin Peptides Quantified with ICAT Labels IS : Inter-IS Average Error from 1:1 
LCYVALDFEQEMATAASSSSLEK 0.94 : 1  
0.07 = 7% 
 
CPEALFQPSFLGMESCGIHETTFNSIMK 0.90 : 1 
CDVDIR 1 : 0.95 
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ICAT measured expression levels of some proteins with important roles in 
implantation are listed below (% higher in IS).  *Also observed to increase in the 
profiling/ imaging studies, ^Proteins known to be increased in IS 
 
Alpha-2-macroglobulin / pregnancy zone protein (80%)^, Protein Disulfide 
Isomerase A3 (66%), Transferrin (57%), 40S ribosomal protein S28 and S21 
(35% and 22%)*, Alpha-2-HS-glycoprotein (33%)^, Stress induced 
phosphoprotein (30%), Hemopexin (30%), Implantation serine proteinase 
(28%)^, Thioredoxin 1 (28%)*, Esterase (26%), Calreticulin (24%), Complement 
C3 (23%), Antithrombin (20%), Macrophage Migration Inhibitory Factor 
(Decreased 25% in IS)*  
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Table 4.  Proteins which also show differential expression patterns between the various cell 
types on day 6 of pregnancy are listed. 
MW 
(Da) 
Protein Name 
% coverage of 
unprocessed 
precursor 
Modifications 
(amino acid 
chain) 
Swissprot 
Primary 
Accession 
Number 
TPP 
Cellular 
Region with 
High 
Expression 
Primary Functions and Processes of the 
Protein 
Proteins Expressed in the Muscle 
4964  Thymosin Beta 4  38  * (8 ‐ 50)  P20065  0.88 
Muscle and 
M pole ' 
Cytoskeleton organization, Regulation of cell 
migration 
6718  Purkinje cell protein 4  44.3  * (2 ‐ 62)  P63054  1  Muscle '  Calcium ion binding 
7413 
Purkinje cell like 
protein 4 ‐ like 1 
60.3  * (2 ‐ 68)  Q6W8Q3  1  Muscle ' 
 
Proteins Expressed in the Anti‐Mesometrial Pole 
6120 
Serine Protease 
inhibitor Kazal‐type 3 
56.2 
 (3 disulfide) 
(24 ‐ 80) 
P09036  1  AM 
Serine‐type endopeptidase inhibitor activity, 
Endopeptidase inhibitor activity 
10951  Calgizzarin  37.8   (2 ‐ 98)  P50543  1 
AM and 
PDZ 
Cytokine activity, Calcium ion binding 
Proteins Expressed in the Mesometrial Pole 
8906  Apolipoprotein AII  51  * (24 ‐ 102)  P09813  1  M  Lipid binding and transport  
12131  Cytochrome C somatic  41.9  *, # (2 ‐ 105)  P62897  1  M  Positive regulation of apoptosis  
12373 
Macrophage migration 
inhibitory factor 
36   (2 ‐ 115)  P34884  1  M  Inflammatory response 
14954 
Hemoglobin alpha 
chain 
62.7   (2 ‐ 142)  P01942  1  M '  Oxygen transport 
15709 
hemoglobin beta chain 
1 
97.3   (2 ‐ 147)  P02088  1  M'  Oxygen transport 
15747 
hemoglobin beta chain 
2 
96.6   (2 ‐ 147)  P02089  1  M'  Oxygen transport 
Proteins Expressed in the Secondary Decidual Zone 
6546 
40S ribosomal protein 
S29 
18.8   (2‐56)  P62274  1  SDZ  Translation 
7883 
40S ribosomal protein 
S28 
13  * (1 ‐ 69)  P62858  1  SDZ  Translation 
8073 
60S ribosomal protein 
L38 
50   (2 ‐ 70)  Q9JJI8  1  SDZ  Translation 
8105 
ATP synthase F1F0 
subunit e 
61.4   ( 2‐71)  Q5EBI8  1  SDZ  ATP synthesis coupled proton transport  
8945 
ATP synthase Coupling 
Factor 6 
40.7   (33 ‐ 108)  P97450  1  SDZ  ATP synthesis coupled proton transport  
9183 
40S Ribosomal Protein 
S21 
39.8  * (1 ‐ 83)  Q9CQR2  1  SDZ  Translation 
9982 
Cytochrome c oxidase 
subunit Vib isoform 1 
41.2  * (2 ‐ 86)  P56391  1  SDZ  Electron transport 
10873 
10KDa heat shock 
protein 
67.6  * (2 ‐ 102)  Q64433  1  SDZ  Protein folding 
11811 
60S acidic ribosomal 
protein P2 
84.3 
S17^,S102^  
 (1‐115) 
P99027  1  SDZ  Translation 
13640  Transthyretin  61.9   (21 ‐ 147)  P07309  1 
SDZ and 
AM 
Thyroid hormone generation, Transport 
*acetylated N‐terminus (+42 Da),  ^Phosphorylation (+80 Da),  # heme group (+615 Da),  
‘muscle localization was determined by IMS not statistical analysis 
TTP:  Trans‐Proteomic Pipeline probability score 
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Table 4 (Continued).  Proteins which also show differential expression patterns 
between the various cell types on day 6 of pregnancy are listed. 
MW 
(Da) 
Protein Name 
% coverage of 
unprocessed 
precursor 
Modifications 
 (amino acid 
chain) 
Swissprot 
Primary 
Accession 
Number 
TPP 
Cellular 
Region with 
High 
Expression 
Primary Functions and Processes of 
the Protein 
Proteins Expressed in the Primary Decidual Zone 
6157  Metallothionein‐2  13.1  * (1‐61)  P02798  1  PDZ 
Cellular zinc ion homeostasis, 
Detoxification of copper ion, Nitric 
oxide mediated signal transduction  
8193 
 
Homeodomain only 
protein 
 
31.9  * (2‐73)  Q8R1H0  1  PDZ  Regulation of transcription 
9911 
 
Acyl CoA binding 
protein 
 
46  * (2 ‐ 87)  P31786  1  PDZ  Transport 
9961 
 
Calcyclin 
 
67.4  * (2 ‐ 89)  P14069  1  PDZ 
Cell cycle, Cell proliferation, 
Regulation of progression through 
cell cycle 
11088 
 
Cystatin B 
 
56.1  * (1 ‐ 98)  Q62426  1  PDZ 
Cysteine protease inhibitor activity, 
Endopeptidase inhibitor activity, 
Protease binding 
11544 
 
Thioredoxin 1 
 
56.2   (2 ‐ 105)  P10639  1  PDZ  Cell redox homeostasis  
11791 
 
FK 506‐binding protein 
1A 
 
29.6   (2 ‐ 108)  P26883  1  PDZ 
Isomerase activity, Protein folding,  
Transport 
Proteins Expressed throughout the Implantation Site 
6653 
 
Cytochrome C oxidase 
copper chaperone 
 
25.8   (2 ‐ 63)  P56394  0.99  IS  Copper chaperone activity  
8565  Ubiquitin  91.8   (24 ‐ 102)  P62991  1  IS  Protein degeradation 
Proteins Expressed throughout the Interimplantation Site 
11347  Histone H4  57.7  P62806  1  Inter‐IS  Nucleosome assembly  
13804  Histone H2B  24.6 
 
Q9FFC0  1 
Inter‐IS and 
SDZ 
Nucleosome assembly  
14006 
14047 
Histone H2A2  27.1 
 
Q6GSS7  1 
Inter‐IS and 
SDZ 
Nucleosome assembly  
Proteins not Expressed in specific regions 
6088 
 
Probable 
Mitochondrial Import 
Receptor Subunit 
TOM7 Homolog 
 
30.9  * (2 ‐ 55)  Q9D173  1 
 
Transport 
6573 
 
Cytochrome C oxidase 
polypeptide VIIA 
 
12   (24‐83)  P48771  0.97 
 
Electron transport 
7207 
 
Copper Transport 
Protein ATOX1 
 
58.8   (2 ‐ 68)  O08997  1 
 
Copper transport 
10901 
 
Dynein Cytoplasmic 
light chain 2a 
 
73.7  * (2 ‐ 96)  P62627  1 
 
Microtubule‐based movement, 
Small GTPase mediated signal 
transduction 
11055 
 
Calpactin 1 light chain 
 
27.8   (2 ‐ 97)  P08207  1 
 
Regulation of cell differentiation, 
Regulation of cell growth 
11687  Beta‐2 microglobulin  35   (21 ‐ 119)  P01887  1 
 
Immune response, Antigen 
processing and presentation of 
peptide antigen via MHC class I  
12165  Prothymosin alpha  22.7   (2 ‐ 111)  P26350  1  Immune response 
12772  Myotrophin  25.6  * (2 ‐ 118)  P62774  1  Protein binding 
14777 
Lectin galactose 
binding soluble 1 
61.5  * (2 ‐ 135)  P16045  1 
 
Cell adhesion 
*acetylated N‐terminus (+42 Da) 
TTP:  Trans‐Proteomic Pipeline probability score 
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CHAPTER V 
 
CONCLUSIONS AND PERSPECTIVES 
 
A.  Discussion of protein and phospholipid localization patterns during 
early pregnancy 
This study found that small structural changes in phospholipids have a 
huge impact on their spatial distribution across implantation sites and, as a result, 
their biological activity.  In addition, proteins important to biological processes of 
embryo implantation are highly regionalized and take place in very discrete time 
domains.  In Figures 33 – 41 protein and phospholipid images are categorized 
according to their expression patterns on different days of embryo implantation.  
Proteins with increased expression levels on day 4 of pregnancy include actin 
sequestering proteins, thymosin β4 and β10, which plays roles in regulation of 
actin polymerization (Figure 33).  These proteins are known to be involved in cell 
proliferation, migration, and differentiation, all cellular processes which play 
important roles in priming the receptive uterus.  In day 4 implantation sites most 
phospholipids show an intensity increase in the lumen (Figure 34).  An exception 
is PC 32:0 which localizes to the uterine stroma; this phospholipid shows an 
inverse localization pattern in comparison to the other phospholipids throughout 
embryo implantation.  Proteins with increased expression in the luminal epithelial 
cells on day 5 of pregnancy; such as, ATP synthase F1F0 subunit e, and 
cytochrome c oxidase subunit VIb isoform 1 play a role in energy production 
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(Figure 35).  In day 5 implantation sites most phospholipids show an intensity 
increase in the uterine stroma immediately surrounding the implanting embryo 
(Figure 36).  Proteins implicated in hormone signaling and proliferating localize 
to the PDZ and SDZ of day 6 implantation sites, respectively (Figure 37).  On 
day 6 of implantation most of the phospholipids showed an intensity increase in 
the PDZ (Figure 38).  Some of these phospholipids are starting to localize to the 
M pole (PC 34:1 [16:0/18:1] and PI 38:5 [18:1/20:4]), whereas others are 
localizing to the AM pole (PC 36:2 [18:0/18:2] and PC 36:4 [16:0/20:4]).  Proteins 
that show the highest intensity on day 8 of pregnancy, such as, cystatin B and 
acyl CoA binding protein localize to embryo and are implicated in embryo survival 
(Figure 39).  On day 8 of pregnancy, phospholipids localized to either the M pole 
or AM pole of the implantation sites (Figure 40).  Oleate (18:1) containing 
phospholipids and arachidonate (20:4) containing PEs and PIs localize to the M 
pole.  Linoleate (18:2) and docosahexaenoate (22:6) containing phospholipids 
and arachidonate (20:4) containing PCs localize to the AM pole.  Strikingly, 
MALDI images of 18:1 (PC 34:1, PC 36:1 and PS 36:1) and 18:2 (PC 34:2, PC 
36:2 and PS 36:2) containing phospholipids show that they localize to completely 
different hemispheres of the day 8 implantation sites, yet the only structural 
change between these phospholipids is one double bond in the sn2 fatty acid 
chain.  Potential angiogenic and apoptotic roles for phospholipids in the M and 
AM poles of day 8 implantation sites are discussed in the following section.  
Purkinje cell protein 4 (PEP-19) and purkinje cell protein 4 like 1 proteins show 
constant expression during the implantation process because they localize the 
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muscle layer encircling the uterine stroma, which is unaffected by the 
decidualization process resulting from the presence of the embryo (Figure 41).   
Figures 33 – 41 also show the unparalleled ability of MALDI IMS to 
spatially resolve posttranslational modified proteins form their intact forms.  
Figure 35 depicts a truncated form of ubiquitin which is missing two c-terminal 
glycines (G) (Figure 35).  This modified ubiquitin has been characterized in many 
different pathological and physiological biological processes 139.  
Posttranslational modified forms of apolipoprotein A-II, missing its c-terminal 
lysine (K), and serine protease inhibitor kazal-type3, missing its n-terminal 
alanine (A) and K were also detected by imaging MS (Figure 37).   
Based on our studies discussed in chapter IV, it was known that proteins 
can also show expression/distribution patterns in the M and AM poles on day 8 of 
pregnancy, similar to that seen in the lipid images in this study 113.  To explore 
this further, protein images of a day 8 implantation site were generated that 
showed high expression levels in either the M or AM pole (Figure 42).  In Figure 
39, ATP synthase coupling factor 6, thymosin β4, FK506-binding protein 1A, and 
macrophage migration inhibitory factor localized to the M pole.  These proteins 
have been shown to play important roles in angiogenesis 140-144.  Calgizzarin and 
calcyclin localized to the uterine cells in the AM pole, whereas, homeodomain 
only protein, and cystatin B localize to the embryo in the AM pole.  The edge of 
the embryo is depicted by homeodomain-only protein that is expressed in 
embryonic trophoblast cells145.  This is consistent with other data that show 
calgizzarin and calcyclin to be important in cell apoptosis, while cystatin B 
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prevents apoptosis 146, 147.  In summary, with respect to proteins, images on day 
8 of pregnancy revealed an increased level of proteins involved in angiogenesis 
at the uterine stroma at the M pole and those involved in apoptosis to the uterine 
stroma in the AM pole.  This is consistent with known biology, on day 8 of 
pregnancy where cells at the M pole are preparing for rapid development of the 
placenta by initiating angiogenesis; cells at the AM pole are preparing for embryo 
growth by undergoing apoptosis. 
 In summary, this work focuses on technology that provides both spatial 
and temporal molecular analyses in the elucidation of critical events in the 
reproductive process.  Here for the first time, we use Imaging Mass Spectrometry 
to elucidate the spatial patterning of lipids and proteins during embryo 
implantation and demonstrate its value in helping to understand fertility and the 
reproductive process.  For example, our analysis clearly shows previously 
unknown molecular distributions of lipids over time in this system.  Beyond this 
example, we think that the approach and the concepts illustrated in this work will 
be of enormous value in various areas of biology and will be critical for 
understanding many biological processes. 
 Implantation is an incredibly important biological process, a better 
understanding of which will advance our knowledge in several basic physiological 
processes.  For example, several reports have noted an interesting parallel 
between implantation and cancer in that many cellular processes such as tissue 
invasion, replicative potential, and angiogenesis, which are required during 
implantation, are also important during tumorigenesis 1, 48, 148.  During embryo 
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implantation the tissue microenvironment has the ability to tightly regulate these 
events, while dysregulation of these events may lead to cancer.  Some of the 
phospholipids analyzed in this study are known to play important roles in cancer 
proliferation, survival and migration.  It has previously been reported that in 
cancer linoleate can promote cancer cell growth 149, whereas, docosahexaenoate 
has been shown to inhibit cancer cell growth by preventing neovascularization 
146, 150.  Understanding the molecular events driving cellular transformations 
during embryo implantation may shed light on similar processes occurring in 
other biological processes involving cell proliferation. 
 
B.  Future Outlook: Advancements in IMS 
IMS continues to advance at an accelerating rate moving toward higher 
spatial resolution and wider applicability.  The size of the focused MALDI laser 
beam, matrix spots in an array, and matrix crystal size in a sprayed or spotted 
matrix coating, all determine the lateral image resolution (surface area mapped 
by a single pixel) in an IMS experiment.  Therefore, IMS analysis of individual 
cells is at present a laborious endeavor.  As the technology advances, submicron 
dimension of both the laser and matrix crystals will enable IMS experiments to 
explore subcellular molecular compositions.   
The molecular complexity of biological systems obviates the need for 
molecularly specific tools to elucidate proteomic events in both spatial and 
temporal distributions.  Parallel analysis of hundreds of molecular species by IMS 
without the need for target-specific reagents such as florescence tags or 
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antibodies provides investigators with a unique tool for studying pathological and 
physiological biological processes.  Moreover, this technology appeals to the 
human intellect and to our ability to understand complexity in a visual format.  
With continued developments in the field, IMS can become even more 
comprehensive and powerful with the potential to become an important and 
routine analysis for clinical, pharmaceutical and laboratory practice. 
Furthermore, the massive amount of information produced by new 
technologies, such as, MALDI IMS, has ushered in a new era where instead of 
identifying individual biomolecules and studying their specific function, 
researchers hope to understand how these biomolecules function in context of 
the integrated system.  Organisms are not static systems; they are integrated 
and interacting networks of genes, gene transcripts, proteins, lipids and 
biochemical reactions.  IMS is a powerful tool for systems biology applications 
since it has the ability to analyze each of these networks; thereby, providing 
insight into highly structured but incredibly complex ways these molecules 
interact. 
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